Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Infectious Diseases›Condition·Updated Jul 11, 2026·v1

Tuberculosis

Tuberculosis is a curable airborne infection caused by Mycobacterium tuberculosis that requires a high index of suspicion due to frequent subclinical presentation. Rapid diagnosis with Xpert MTB/RIF Ultra and combination chemotherapy tailored to drug susceptibility achieve cure in >90% of cases. New short-course regimens, 4 months for drug-susceptible TB and 6 months all-oral BPaLM for MDR-TB, have transformed outcomes. Management must address HIV co-infection (adjust ART dosing), monitor for drug toxicity (linezolid neuropathy, hepatotoxicity), and plan for post-treatment pulmonary and cardiovascular sequelae. Adherence through DOT, universal drug susceptibility testing, and aggressive management of risk factors (diabetes, undernutrition) are critical to preventing relapse and resistance.

High Evidence743 references·1,961 words·8 min read·v1
tuberculosisMycobacterium tuberculosispulmonary tuberculosisextrapulmonary tuberculosisMDR-TBXDR-TBlatent tuberculosis infectionTB treatmentrifapentinebedaquilinepretomanidlinezolidXpert MTB/RIFtuberculous meningitispost-TB lung diseaseHIV-TB co-infectiondirectly observed therapydrug susceptibility testing

Quick Reference

RxDrug of choiceDrug-susceptible TB: rifampicin 10 mg/kg (max 600 mg) + isoniazid 5 mg/kg (max 300 mg) + pyrazinamide 25 mg/kg (max 2 g) + ethambutol 15-20 mg/kg daily for 2 months, then rifampicin + isoniazid daily for 4 months. MDR-TB: BPaLM regimen, bedaquiline 400 mg daily for 2 weeks then 200 mg 3×/week, pretomanid 200 mg daily, linezolid 600 mg daily, moxifloxacin 400 mg daily for 24 weeks.
AltAlternativesRifapentine (1200 mg daily, substitute for rifampicin in 4-month regimen), moxifloxacin (400 mg daily, added for short-course or MDR), bedaquiline (for MDR), linezolid (600 mg daily, reduce to 300 mg if toxicity), pretomanid (200 mg daily), delamanid (100 mg twice daily), clofazimine (100 mg daily), levofloxacin (1000 mg daily).
⊘AvoidIntermittent (thrice-weekly) dosing in HIV-associated TB; non-dihydropyridine CCBs (diltiazem, verapamil) in TB with heart failure; rifampicin when resistance confirmed; isoniazid in acute liver failure without alternative; nevirapine with rifampicin.
DxTest of choiceXpert MTB/RIF Ultra on sputum (or appropriate extrapulmonary specimen), simultaneously detects M. tuberculosis complex and rifampicin resistance, turnaround ~1 hour, sensitivity 88% overall. Culture remains gold standard for definitive diagnosis and comprehensive DST.
ScKey scoreRIFASHORT phenotype (Xpert semiquantitative burden + chest radiograph disease extent) to determine eligibility for 4-month regimen; MRC stage (I-III) and validated prognostic nomogram (AUC 0.77-0.78) for tuberculous meningitis severity; 16-gene whole-blood signature for predicting progression from latent to active TB.
→When to referMDR/XDR-TB, tuberculous meningitis, treatment failure, complex drug interactions (HIV, transplant, pregnancy), children <5 years, need for surgical management (e.g., massive hemoptysis), drug intolerance, or retreatment after loss to follow-up.
TB is curable with timely diagnosis using molecular testing and appropriate combination therapy; new short-course regimens (4 months for DS-TB, 6 months for MDR-TB with BPaLM) improve adherence and outcomes, ensure drug susceptibility testing, daily DOT, and management of comorbidities.
Tuberculosis (TB) is a leading infectious cause of death worldwide, caused by *Mycobacterium tuberculosis*. Subclinical disease without cough is common, affecting 82.8% of community cases. Diagnosis relies on molecular testing (Xpert Ultra). Treatment includes 6-month regimen for drug-sensitive TB and all-oral short regimens for drug-resistant TB. Prevention focuses on LTBI treatment and infection control.

Overview and Recommendations

Background

  • •Tuberculosis (TB), caused by the Mycobacterium tuberculosis complex, is the leading infectious cause of death globally, with an estimated 10 million new cases and 1.5 million deaths annually. Despite being curable, TB remains a major public health threat driven by airborne transmission, slow diagnosis, and rising drug resistance, multidrug-resistant TB (MDR-TB) now accounts for nearly 500,000 new cases yearly.
  • •The disease spectrum ranges from asymptomatic latent infection (LTBI) to active pulmonary and extrapulmonary disease. Approximately one-quarter of the world's population harbors LTBI, with a 5-10% lifetime risk of progression, concentrated in the first 2 years after infection. Subclinical TB, bacteriologically confirmed without symptoms, accounts for ~50% of prevalent cases in community surveys and contributes to transmission despite the absence of cough.
  • •Pulmonary TB constitutes 70-80% of cases, but extrapulmonary involvement (lymphatic, pleural, meningeal, miliary) is common, especially in co-infection and children. (TBM) carries a 50% risk of death or severe neurologic disability even with treatment. The hallmark of progressive TB is caseating granuloma formation; failure of granuloma containment leads to cavity formation, dissemination, and hemoptysis.
  • •Risk factors include HIV (20- to 37-fold increased risk), diabetes mellitus (2- to 3-fold), undernutrition (BMI <18.5), smoking, alcohol use (>40 g/day), therapy, end-stage renal disease, and close contact with an infectious case. Social determinants, poverty, crowding, incarceration, amplify transmission. The of M. tuberculosis is associated with enhanced virulence and drug resistance.
  • •A paradigm shift has occurred in TB treatment: drug-susceptible TB can be treated in 4 months with a
    regimen (Study 31/A5349, 2021), and MDR-TB can be cured in 6 months with all-oral
    (BPaLM, TB-PRACTECAL trial, 2022). These regimens replace older 18-24 month injectable-containing therapies, improving adherence and reducing toxicity.

Evaluation

  • •Suspect active TB in any patient with cough lasting ≥2 weeks, unexplained fever, night sweats, weight loss, or hemoptysis. However, over 50% of culture-positive individuals in community prevalence surveys report no persistent cough, and ~25% have no symptoms at all, maintain a high index of suspicion regardless of symptom profile, particularly in endemic areas or high-risk groups.
  • •Ask about prior TB treatment (risk of drug resistance), exposure to known cases, travel from or residence in endemic regions, HIV status, diabetes, immunosuppressive medications (especially agents), alcohol/tobacco use, and history of incarceration or homelessness.
  • •Examine for cervical lymphadenopathy (matted, painless, may fistulize), pulmonary crackles or signs of consolidation, pleural effusion, and in severe cases meningeal signs (neck stiffness, cranial nerve palsies) suggesting . Assess for hepatosplenomegaly in miliary disease and signs of adrenal insufficiency (hyponatremia, hypotension) in disseminated TB.
  • •Order a posteroanterior chest radiograph as initial imaging. Classic findings are upper-lobe infiltrates with cavitation, but HIV-positive patients more often have lower-lobe, interstitial, or miliary patterns. Chest CT provides greater sensitivity for small nodules, lymphadenopathy, and pleural effusion, useful when radiograph is equivocal.
  • •Collect two sputum specimens (one spot, one early-morning) for and mycobacterial culture. Xpert Ultra has 88% sensitivity overall (90% in HIV-positive, 63% in smear-negative cases) and simultaneously detects resistance with >95% sensitivity. Culture on liquid (MGIT) or solid media remains the gold standard for definitive diagnosis and comprehensive phenotypic drug susceptibility testing.
  • •If sputum is unavailable or negative with high suspicion, obtain bronchoalveolar lavage (BAL), induced sputum, or gastric aspirate (especially in children). For extrapulmonary TB, test appropriate specimens: (for TBM, send Xpert Ultra, culture, and consider adenosine deaminase [ADA]; cut-off ~40 U/L supports diagnosis), pleural fluid, pericardial fluid, pus from lymph nodes, or tissue biopsy for histology (caseating granuloma) and molecular testing.
  • •Perform expanded drug susceptibility testing when rifampicin resistance is detected or in high-risk patients. Use (tNGS) directly on sputum for rapid detection of resistance to first- and second-line drugs (isoniazid, fluoroquinolones, bedaquiline, linezolid) with >95% sensitivity and specificity. Whole-genome sequencing from cultured isolates provides the most comprehensive resistance profile.
  • •Apply severity stratification at diagnosis: classify pulmonary TB as extensive (high Xpert semiquantitative bacterial burden + extensive radiographic disease [cavitation grade ≥2]) versus limited disease. The phenotype identifies patients eligible for shortened 4-month therapy, those with extensive disease account for over half of post-treatment relapses and require full 6-month regimens. Time-to-detection <9 days in liquid culture identifies patients at high risk of transmission (OR 2.56).
  • •For , use the MRC stage (stage I: alert; II: confused; III: comatose) and validated prognostic models that incorporate age, neurological signs, CSF lymphocyte count, and HIV status. The model achieves AUC 0.77-0.78 and is available as a web-based nomogram for bedside risk estimation. High CSF neutrophil count and culture positivity at diagnosis predict subsequent IRIS (RR 9.3).
  • •Consider alternative diagnoses: (require culture identification), fungal infections ( , , in endemic areas), lung cancer (especially cavitating squamous cell carcinoma), sarcoidosis (non-caseating granulomas), and necrotizing bacterial pneumonia. In HIV, also consider pneumonia and disseminated fungal disease.
  • •Assess for complications at initial evaluation: hemoptysis, from bronchiectasis or (mortality up to 50% if massive); acute respiratory failure, from extensive pulmonary or miliary disease; and adrenal insufficiency, suspected with hyponatremia, hyperkalemia, hypotension (33% pooled prevalence in TB patients).

Management

  • •Initiate standard therapy for drug-susceptible pulmonary TB immediately upon microbiologic confirmation: a 2-month intensive phase of 10 mg/kg (max 600 mg) daily, 5 mg/kg (max 300 mg) daily, 25 mg/kg (max 2 g) daily, and 15-20 mg/kg (max 1.6 g) daily, followed by a 4-month continuation phase of rifampicin and isoniazid daily. Administer with pyridoxine 25-50 mg daily to prevent isoniazid-induced peripheral neuropathy.
  • •Offer a shortened 4-month regimen for eligible drug-susceptible TB patients with limited disease (low bacterial burden and non-cavitary or minimal cavitation): substitute 1200 mg daily for rifampicin and add 400 mg daily, with the same companion drugs for 2 months followed by rifapentine-moxifloxacin for 2 months. This regimen is noninferior to the 6-month standard (unfavorable 11.6% vs 9.6%) and is safe in HIV with CD4 ≥100 cells/μL on efavirenz-based ART. Exclude patients with extensive disease (high Xpert burden + cavitation/extensive infiltrates).
  • •For rifampicin-resistant or multidrug-resistant TB (MDR-TB), initiate a 24-week all-oral BPaLM regimen: 400 mg daily for 2 weeks then 200 mg three times weekly, 200 mg daily, 600 mg daily, and 400 mg daily. This regimen is superior to standard care (11% vs 48% unfavorable outcomes; risk difference -37 percentage points). For fluoroquinolone-resistant strains (pre-XDR), use BPaL (omit moxifloxacin).
  • •Alternative all-oral 9-month regimens for fluoroquinolone-susceptible MDR-TB include BCLLfxZ (bedaquiline 400 mg daily for 2 wk then 200 mg 3×/wk, 100 mg daily, linezolid 600 mg daily, 1000 mg daily, pyrazinamide 25 mg/kg daily), BLMZ (bedaquiline, linezolid, moxifloxacin, pyrazinamide), or BDLLfxZ (bedaquiline, 100 mg twice daily, linezolid, levofloxacin, pyrazinamide) based on the endTB trial, all noninferior to standard therapy.
  • •Monitor linezolid toxicity closely: peripheral neuropathy occurs in up to 38% and myelosuppression in 2-22% at 600 mg daily. Perform weekly CBC for the first 2 months, then monthly. Measure linezolid trough concentration, aim for <2 μg/mL to reduce toxicity. If trough >2 μg/mL or toxicity develops, reduce linezolid to 300 mg daily after 9-13 weeks; this dose maintains efficacy while significantly reducing adverse events (neuropathy 8% vs 14%, P = .02).
  • •Use directly observed therapy (DOT) or video-supported therapy for every dose to ensure adherence and prevent acquired drug resistance. Daily dosing throughout treatment is recommended, avoid intermittent (thrice-weekly) dosing, especially in HIV-associated TB, where it increases failure (adjusted RR 4.0) and relapse (adjusted RR 4.8).
  • •In patients with co-infection, start antiretroviral therapy (ART) within 2-8 weeks of TB treatment (earlier if CD4 <50 cells/μL, but monitor for IRIS). Adjust to 50 mg twice daily when co-administered with rifampicin (rifampicin induces UGT1A1 and CYP3A4). 600 mg daily requires no adjustment; requires 400 mg twice daily. is not recommended with rifampicin. Immune reconstitution inflammatory syndrome (IRIS) occurs in ~16% of HIV/TB patients, typically within 4-8 weeks of ART initiation, treat with NSAIDs or corticosteroids if symptomatic.
  • •For , administer adjunctive 0.4 mg/kg/day IV/PO (tapered over 6-8 weeks) in all patients regardless of HIV status, reduces mortality and neurologic sequelae. For severe disease, consider high-dose rifampicin (35 mg/kg IV or 30 mg/kg orally) for improved outcomes, but monitor for hepatotoxicity. Maintain standard isoniazid, pyrazinamide, and ethambutol doses. Monitor for hyponatremia ( is common) and raised intracranial pressure.
  • •In children with nonsevere, smear-negative, drug-susceptible TB, treat with 4 months of standard therapy (2HRZE/2HR) as per the SHINE trial, noninferior to 6 months (unfavorable 3% vs 3%). Use pediatric fixed-dose combinations and weight-based dosing. For severe TB (miliary, meningitis, bone/joint), extend treatment to 6-12 months. For children exposed to MDR-TB, offer 6 months of levofloxacin preventive therapy (TB-CHAMP trial, 56% reduction in TB incidence).
  • •What NOT to do: Do not continue a rifampicin-based regimen when rifampicin resistance is confirmed by molecular or phenotypic testing. Do not use monotherapy or add a single new drug to a failing regimen, functional monotherapy is the strongest driver of acquired resistance. Do not use intermittent dosing in the intensive phase for HIV-positive patients. Do not use non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in TB patients with heart failure, they are contraindicated and worsen outcomes.
  • •Refer to a TB specialist or infectious disease consultant for: MDR/XDR-TB, tuberculous meningitis, treatment failure (positive culture after 2 months), drug intolerance or hepatotoxicity, pregnancy, children <5 years, or when surgical intervention (e.g., for massive hemoptysis from Rasmussen aneurysm) is needed. For MDR-TB, consultation with a national TB reference laboratory for expanded DST is essential.
  • •After treatment completion, monitor for post-TB lung disease: assess respiratory symptoms and perform spirometry at 3-6 months. Over 50% of survivors have chronic airflow obstruction, bronchiectasis, or impaired diffusing capacity, manage with bronchodilators, airway clearance, and smoking cessation. Screen for (1-year mortality 15%) if new cavitation or hemoptysis. Manage cardiovascular risk factors aggressively, TB survivors have a 21% higher risk of ischemic heart disease (aHR 1.21) and 48% higher risk of myocardial infarction.

Board Review — High Yield

  • •Subclinical TB, Over 50% of culture-positive pulmonary TB cases in community surveys do not report persistent cough; maintain a high index of suspicion regardless of symptoms, 23% of cough-free individuals have positive sputum smears.
  • •Xpert MTB/RIF Ultra, First-line diagnostic test with 88% sensitivity (63% in smear-negative); detects rifampicin resistance simultaneously; preferred over smear microscopy for initial diagnosis.
  • •4-month regimen, Rifapentine-moxifloxacin-based regimen is noninferior to standard 6-month therapy for drug-susceptible TB in patients without extensive disease (RIFASHORT phenotype).
  • •BPaLM for MDR-TB, 24-week all-oral regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) achieved 11% unfavorable outcomes vs 48% with standard care in TB-PRACTECAL trial; use BPaL if fluoroquinolone-resistant.
  • •Linezolid toxicity, Peripheral neuropathy (up to 38%) and myelosuppression (2-22%) are dose-limiting; reduce to 300 mg daily after 9-13 weeks if trough >2 μg/mL or toxicity occurs, maintains efficacy, reduces harm.
  • •Rifampicin-dolutegravir interaction, Double dolutegravir to 50 mg twice daily when co-administered with rifampicin (rifampicin induces UGT1A1 and CYP3A4); efavirenz and raltegravir (400 mg BID) alternatives.
  • •TBM dexamethasone, Adjunctive dexamethasone 0.4 mg/kg/day tapered over 6-8 weeks reduces mortality and neurologic sequelae in tuberculous meningitis; use in all patients regardless of HIV status.
  • •SHINE trial, Children with nonsevere smear-negative drug-susceptible TB can be treated with 4 months instead of 6 months (unfavorable 3% vs 3%), reduces treatment burden in a vulnerable population.
  • •Post-TB lung disease, Over 50% of survivors have chronic pulmonary impairment (airflow obstruction, bronchiectasis, impaired diffusing capacity); assess spirometry at treatment completion and monitor for chronic pulmonary aspergillosis.
  • •Preventive therapy for MDR contacts, Levofloxacin 6 months reduces TB incidence among household contacts of MDR-TB patients (adults: IRR 0.55; children: HR 0.44), now recommended by WHO.

Deep Dive — Evidence Details

References

  1. [1]

    Nahid P, Dorman SE, Alipanah N et al.. “Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2016). PMID: 27516382 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  2. [2]

    Lewinsohn DM, Leonard MK, LoBue PA et al.. “Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28052967 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Special Hosts and Populations
  3. [3]

    Lewinsohn DM, Leonard MK, LoBue PA et al.. “Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2016). PMID: 27932390 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, History and Evolution of Treatment
  4. [4]

    Donovan J, Cresswell FV, Tucker EW et al.. “A clinical practice guideline for tuberculous meningitis.” The Lancet. Infectious diseases (2025). PMID: 40840485 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History
  5. [5]

    Pettit AC, Phillips PPJ, Kurbatova E et al.. “Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36041016 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Hosts and Populations
  6. [6]

    Ndege R, Ngome O, Vanobberghen F et al.. “Ultrasononography in Managing Extrapulmonary Tuberculosis: A Randomized, Controlled, Parallel, Superiority, Open-Label Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36331957 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, History and Evolution of Treatment, Prognosis and Natural History
  7. [7]

    Schwab TC, Perrig L, Göller PC et al.. “Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2024). PMID: 38795712 ↗

    L1SR_OBSCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  8. [8]

    Paton NI, Cousins C, Sari IP et al.. “Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial.” The Lancet. Infectious diseases (2025). PMID: 40414233 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  9. [9]

    Cevik M, Thompson LC, Upton C et al.. “Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.” The Lancet. Infectious diseases (2024). PMID: 38768617 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History, Special Hosts and Populations
  10. [10]

    Conradie F, Badat T, Poswa A et al.. “A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis.” The New England journal of medicine (2026). PMID: 42341301 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Hosts and Populations
  11. [11]

    Gler MT, Skripconoka V, Sanchez-Garavito E et al.. “Delamanid for multidrug-resistant pulmonary tuberculosis.” The New England journal of medicine (2012). PMID: 22670901 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship
  12. [12]

    Marks GB, Nguyen NV, Nguyen PTB et al.. “Community-wide Screening for Tuberculosis in a High-Prevalence Setting.” The New England journal of medicine (2019). PMID: 31577876 ↗

    L2RCTCited in: Definition, Classification and Causative Organisms
  13. [13]

    Colangeli R, Jedrey H, Kim S et al.. “Bacterial Factors That Predict Relapse after Tuberculosis Therapy.” The New England journal of medicine (2018). PMID: 30157391 ↗

    L3RCTCited in: Definition, Classification and Causative Organisms
  14. [14]

    . “Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.” Lancet (London, England) (2022). PMID: 35065702 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  15. [15]

    Stuck L, Klinkenberg E, Abdelgadir Ali N et al.. “Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis.” The Lancet. Infectious diseases (2024). PMID: 38490237 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Complications
  16. [16]

    Fontanilla JM, Barnes A, von Reyn CF. “Current diagnosis and management of peripheral tuberculous lymphadenitis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21865192 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  17. [17]

    Dawson R, Diacon AH, Everitt D et al.. “Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.” Lancet (London, England) (2015). PMID: 25795076 ↗

    L2RCTCited in: Definition, Classification and Causative Organisms
  18. [18]

    Corbett EL, Bandason T, Duong T et al.. “Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial.” Lancet (London, England) (2010). PMID: 20923715 ↗

    L2RCTCited in: Definition, Classification and Causative Organisms
  19. [19]

    Gupta-Wright A, Corbett EL, van Oosterhout JJ et al.. “Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial.” Lancet (London, England) (2018). PMID: 30032978 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms
  20. [20]

    Khan MS, Dar O, Sismanidis C et al.. “Improvement of tuberculosis case detection and reduction of discrepancies between men and women by simple sputum-submission instructions: a pragmatic randomised controlled trial.” Lancet (London, England) (2007). PMID: 17560448 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms
  21. [21]

    Conde MB, Efron A, Loredo C et al.. “Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.” Lancet (London, England) (2009). PMID: 19345831 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms
  22. [22]

    Guglielmetti L, Khan U, Velásquez GE et al.. “Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.” The New England journal of medicine (2025). PMID: 39879593 ↗

    L1TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  23. [23]

    Yerlikaya S, Chirwa M, Ajide B et al.. “Pulmonary Tuberculosis Detection with MiniDock MTB Using Swab Samples.” The New England journal of medicine (2026). PMID: 42054680 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms
  24. [24]

    Imazio M, Gaita F, LeWinter M. “Evaluation and Treatment of Pericarditis: A Systematic Review.” JAMA (2015). PMID: 26461998 ↗

    L5SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  25. [25]

    Martin A, Panaiotov S, Portaels F et al.. “The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.” The Journal of antimicrobial chemotherapy (2008). PMID: 18407918 ↗

    L3SR_OBSCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  26. [26]

    Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR et al.. “Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis.” The Journal of antimicrobial chemotherapy (2013). PMID: 24055765 ↗

    L5SR_OBSCited in: Definition, Classification and Causative Organisms
  27. [27]

    Granerod J, Ambrose HE, Davies NW et al.. “Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study.” The Lancet. Infectious diseases (2010). PMID: 20952256 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Prognosis and Natural History, Special Hosts and Populations
  28. [28]

    Calderin JM, Wasserman S, Resendiz-Galvan JE et al.. “Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis.” Antimicrobial agents and chemotherapy (2025). PMID: 40590723 ↗

    L4RCTCited in: Definition, Classification and Causative Organisms, History and Evolution of Treatment, Special Hosts and Populations
  29. [29]

    Baussano I, Nunn P, Williams B et al.. “Tuberculosis among health care workers.” Emerging infectious diseases (2011). PMID: 21392441 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Prevention and Infection Control
  30. [30]

    Lange C, Aaby P, Behr MA et al.. “100 years of Mycobacterium bovis bacille Calmette-Guérin.” The Lancet. Infectious diseases (2021). PMID: 34506734 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  31. [31]

    Domínguez J, Boeree MJ, Cambau E et al.. “Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.” The Lancet. Infectious diseases (2023). PMID: 36868253 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  32. [32]

    Newton SM, Brent AJ, Anderson S et al.. “Paediatric tuberculosis.” The Lancet. Infectious diseases (2008). PMID: 18652996 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  33. [33]

    Basu Roy R, Whittaker E, Seddon JA et al.. “Tuberculosis susceptibility and protection in children.” The Lancet. Infectious diseases (2018). PMID: 30322790 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Prognosis and Natural History, Prevention and Infection Control, Special Hosts and Populations
  34. [34]

    Pietersen E, Ignatius E, Streicher EM et al.. “Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study.” Lancet (London, England) (2014). PMID: 24439237 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms
  35. [35]

    Franco-Paredes C, Marcos LA, Henao-Martínez AF et al.. “Cutaneous Mycobacterial Infections.” Clinical microbiology reviews (2018). PMID: 30429139 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control
  36. [36]

    Goossens SN, Sampson SL, Van Rie A. “Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis.” Clinical microbiology reviews (2020). PMID: 33055230 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  37. [37]

    Lagier JC, Edouard S, Pagnier I et al.. “Current and past strategies for bacterial culture in clinical microbiology.” Clinical microbiology reviews (2015). PMID: 25567228 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  38. [38]

    Gopalaswamy R, Subbian S. “The power of resistance: mechanisms of antimicrobial resistance in Mycobacterium tuberculosis and its impact on tuberculosis management.” Clinical microbiology reviews (2026). PMID: 41498549 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  39. [39]

    Hong BY, Maulén NP, Adami AJ et al.. “Microbiome Changes during Tuberculosis and Antituberculous Therapy.” Clinical microbiology reviews (2016). PMID: 27608937 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  40. [40]

    Jagielski T, Minias A, van Ingen J et al.. “Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria.” Clinical microbiology reviews (2016). PMID: 26912567 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  41. [41]

    Suman SK, Chandrasekaran N, Priya Doss CG. “Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments.” Clinical microbiology reviews (2023). PMID: 38032192 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications
  42. [42]

    Rock RB, Olin M, Baker CA et al.. “Central nervous system tuberculosis: pathogenesis and clinical aspects.” Clinical microbiology reviews (2008). PMID: 18400795 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  43. [43]

    Sarathy JP, Dartois V. “Caseum: a Niche for Mycobacterium tuberculosis Drug-Tolerant Persisters.” Clinical microbiology reviews (2020). PMID: 32238365 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  44. [44]

    Cohen T, van Helden PD, Wilson D et al.. “Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control.” Clinical microbiology reviews (2012). PMID: 23034327 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  45. [45]

    Graham SM, Cuevas LE, Jean-Philippe P et al.. “Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26409281 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms
  46. [46]

    Rockman L, Abdulgader SM, Minnies S et al.. “Oral Washes and Tongue Swabs for Xpert MTB/RIF Ultra-Based Tuberculosis Diagnosis in People With and Without the Ability to Make Sputum.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40686067 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  47. [47]

    Solans BP, Imperial MZ, Olugbosi M et al.. “Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36804834 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms
  48. [48]

    Mulenga H, Shenje J, Mendelsohn SC et al.. “Asymptomatic Tuberculosis in Children With Household Exposure to Mycobacterium tuberculosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41092118 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  49. [49]

    Wright A, Zignol M, Van Deun A et al.. “Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance.” Lancet (London, England) (2009). PMID: 19375159 ↗

    L2REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  50. [50]

    Sulis G, Tavaziva G, Gore G et al.. “Comparative Effectiveness of Regimens for Drug-Susceptible Tuberculous Meningitis in Children and Adolescents: A Systematic Review and Aggregate-Level Data Meta-Analysis.” Open forum infectious diseases (2022). PMID: 35673608 ↗

    L1SR_OBSCited in: Definition, Classification and Causative Organisms
  51. [51]

    Wright WF, Yenokyan G, Simner PJ et al.. “Geographic Variation of Infectious Disease Diagnoses Among Patients With Fever of Unknown Origin: A Systematic Review and Meta-analysis.” Open forum infectious diseases (2022). PMID: 35450085 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms
  52. [52]

    Anatory YS, Mmbaga BT, Lyimo B et al.. “Epidemiology of bovine tuberculosis in Tanzania: Systematic review and meta-analysis.” PLoS neglected tropical diseases (2026). PMID: 42406793 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup
  53. [53]

    Shapiro K, Cross SJ, Morton TH et al.. “Healthcare-Associated Infections Caused by Mycolicibacterium neoaurum.” Emerging infectious diseases (2023). PMID: 37486155 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Special Hosts and Populations
  54. [54]

    Maghsoudlou P, Epps SJ, Guly CM et al.. “Uveitis in Adults: A Review.” JAMA (2025). PMID: 40434762 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Complications, Special Hosts and Populations
  55. [55]

    Zhang Y, Yew WW, Barer MR. “Targeting persisters for tuberculosis control.” Antimicrobial agents and chemotherapy (2012). PMID: 22391538 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  56. [56]

    Black PA, Warren RM, Louw GE et al.. “Energy metabolism and drug efflux in Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2014). PMID: 24614376 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship
  57. [57]

    Butler MS, Gigante V, Sati H et al.. “Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.” Antimicrobial agents and chemotherapy (2022). PMID: 35007139 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  58. [58]

    McGrath M, Gey van Pittius NC, van Helden PD et al.. “Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis.” The Journal of antimicrobial chemotherapy (2013). PMID: 24072169 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  59. [59]

    Chung BK, Dick T, Lee DY. “In silico analyses for the discovery of tuberculosis drug targets.” The Journal of antimicrobial chemotherapy (2013). PMID: 23838951 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  60. [60]

    Jaganath D, Schaaf HS, Donald PR. “Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.” The Journal of antimicrobial chemotherapy (2017). PMID: 28333284 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Special Hosts and Populations
  61. [61]

    Gonge S, Gaikwad RS, Jadhav NN et al.. “Digital case-based learning for improving clinical decision-making in tuberculosis care.” The Indian journal of tuberculosis (2026). PMID: 42362245 ↗

    L2RCTCited in: Definition, Classification and Causative Organisms, History and Evolution of Treatment
  62. [62]

    Armstrong GL, MacCannell DR, Taylor J et al.. “Pathogen Genomics in Public Health.” The New England journal of medicine (2019). PMID: 31881145 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms
  63. [63]

    Shah NS, Auld SC, Brust JC et al.. “Transmission of Extensively Drug-Resistant Tuberculosis in South Africa.” The New England journal of medicine (2017). PMID: 28099825 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  64. [64]

    Mitnick CD, Shin SS, Seung KJ et al.. “Comprehensive treatment of extensively drug-resistant tuberculosis.” The New England journal of medicine (2008). PMID: 18687637 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  65. [65]

    Liu Y, Li L, Yang L et al.. “Clinical Features and Treatment Strategies of Q Fever Spinal Infection: A Pooled Analysis of 39 Cases and Narrative Review of the Literature.” Open forum infectious diseases (2025). PMID: 41058886 ↗

    L4REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  66. [66]

    Pai M, Kalantri S, Aggarwal AN et al.. “Nosocomial tuberculosis in India.” Emerging infectious diseases (2006). PMID: 17073077 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Prevention and Infection Control
  67. [67]

    Garcia JU, Zamora RP, Manalo CG et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Infectious Diseases.” Acta medica Philippina (2026). PMID: 42382934 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Special Hosts and Populations
  68. [68]

    Cabaluna ITG, Sulit MVV, Infantado-Alejandro MAJ et al.. “2021 Clinical Practice Guidelines on Periodic Health Examination.” Acta medica Philippina (2026). PMID: 42382929 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms
  69. [69]

    Chau E, Sarkarati M, Spellberg B. “Adenosine Deaminase Diagnostic Testing in Pericardial Fluid.” JAMA (2019). PMID: 31199430 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  70. [70]

    Wang L, Zhang H, Ruan Y et al.. “Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data.” Lancet (London, England) (2014). PMID: 24650955 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  71. [71]

    Gandhi NR, Moll A, Sturm AW et al.. “Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.” Lancet (London, England) (2006). PMID: 17084757 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  72. [72]

    García-Boyano M, Baquero-Artigao F, Toro C et al.. “Mycobacterium mageritense Lymphadenitis in Child.” Emerging infectious diseases (2022). PMID: 35202540 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  73. [73]

    Kumar A, Kunoor A, Eapen M et al.. “Blastomycosis Misdiagnosed as Tuberculosis, India.” Emerging infectious diseases (2019). PMID: 31441756 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  74. [74]

    Guo C, Pan Y, Yu J et al.. “Disseminated Blastomycosis Mimicking Tuberculosis, China.” Emerging infectious diseases (2025). PMID: 41017070 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  75. [75]

    Lobato LS, Rosa PS, Ferreira Jda S et al.. “Statins increase rifampin mycobactericidal effect.” Antimicrobial agents and chemotherapy (2014). PMID: 25049257 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  76. [76]

    Inoyama D, Paget SD, Russo R et al.. “Novel Pyrimidines as Antitubercular Agents.” Antimicrobial agents and chemotherapy (2018). PMID: 29311070 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  77. [77]

    Salinger DH, Subramoney V, Everitt D et al.. “Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.” Antimicrobial agents and chemotherapy (2019). PMID: 31405856 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Special Hosts and Populations
  78. [78]

    Jia Y, Fan J, Tan Z et al.. “An enoyl-ACP reductase inhibitor, NITD-916, expresses anti-Mycobacterium abscessus activity.” Antimicrobial agents and chemotherapy (2025). PMID: 40407337 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  79. [79]

    Rankine-Wilson L, Shapira T, Felker J et al.. “Vacuolar-ATPase inhibitors are antimicrobial agents active against intracellular mycobacteria.” Antimicrobial agents and chemotherapy (2025). PMID: 41170946 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Prognosis and Natural History
  80. [80]

    Ismail N, Sirgel F, Omar SV et al.. “Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing.” Antimicrobial agents and chemotherapy (2025). PMID: 40689761 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Complications
  81. [81]

    Jiang X, Cao D, Qiu Y et al.. “Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare.” The Journal of antimicrobial chemotherapy (2025). PMID: 40905483 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  82. [82]

    Deshpande D, Magombedze G, Srivastava S et al.. “Once-a-week tigecycline for the treatment of drug-resistant TB.” The Journal of antimicrobial chemotherapy (2019). PMID: 30820554 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  83. [83]

    Gumbo T, Srivastava S, Deshpande D et al.. “Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.” The Journal of antimicrobial chemotherapy (2023). PMID: 36794692 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms
  84. [84]

    Kaushik A, Ammerman NC, Tasneen R et al.. “In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.” The Journal of antimicrobial chemotherapy (2017). PMID: 28575382 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms
  85. [85]

    Maitre T, Petitjean G, Chauffour A et al.. “Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?” The Journal of antimicrobial chemotherapy (2017). PMID: 28535203 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  86. [86]

    Lu X, Zhao Y, Qin P et al.. “Metabolic reprogramming of macrophages during mycobacterial infection: a review of immunometabolic crosstalk and pathogen manipulation.” Frontiers in cellular and infection microbiology (2026). PMID: 42422378 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Prognosis and Natural History
  87. [87]

    Wang H, Zhang L. “The functions and inhibitors of protein tyrosine phosphatase B from Mycobacterium tuberculosis.” Frontiers in immunology (2026). PMID: 42327789 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  88. [88]

    Gulleen EA, Holte S, Zhang Y et al.. “Etiology of Fever and Associated Outcomes Among Adults Receiving Chemotherapy for the Treatment of Solid Tumors in Uganda.” Open forum infectious diseases (2023). PMID: 37953812 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis
  89. [89]

    Peng L, Fang T, Dai L et al.. “Diagnostic Value of Cross-priming Amplification Combined With CRISPR-Cas12b in Detecting Cell-free DNA in Tuberculous Pleural Effusion.” Open forum infectious diseases (2024). PMID: 39660021 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  90. [90]

    Pezzoli L, Gounder S, Tamani T et al.. “Tuberculosis, Fiji, 2002-2013.” Emerging infectious diseases (2016). PMID: 26890215 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Special Hosts and Populations
  91. [91]

    Heid-Picard B, Mougari F, Pouvaret A et al.. “Extrapulmonary Mycobacterium abscessus Infections, France, 2012-20201.” Emerging infectious diseases (2024). PMID: 39447147 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
  92. [92]

    Marras TK, Nelson P, Peci A et al.. “Pulmonary Nontuberculous Mycobacteria, Ontario, Canada, 2020.” Emerging infectious diseases (2023). PMID: 37347810 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors
  93. [93]

    El Achkar S, Demanche C, Osman M et al.. “Drug-Resistant Tuberculosis, Lebanon, 2016 - 2017.” Emerging infectious diseases (2019). PMID: 30789124 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  94. [94]

    Gao W, Xia L, Wang J et al.. “Guidelines for the prevention and management of mother-to-child transmission of tuberculosis.” Quantitative imaging in medicine and surgery (2026). PMID: 42433531 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  95. [95]

    Wang M. “Nanopore Sequencing in Mycobacterial Diagnostics: Clinical and Laboratory Roles of mNGS and tNGS.” Diagnostics (Basel, Switzerland) (2026). PMID: 42351509 ↗

    L2REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  96. [96]

    Giusto PS, Augusto M, Francesco L et al.. “Bacterial Granulomatous Lung Diseases: Radiological Findings and Differential Diagnosis.” Infectious disease reports (2026). PMID: 42346060 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  97. [97]

    Rustage K, Lobe J, Hayward SE et al.. “Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2021). PMID: 34363771 ↗

    L1SR_OBSCited in: Microbiology and Pathogenesis
  98. [98]

    Reddy EA, Shaw AV, Crump JA. “Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2010). PMID: 20510282 ↗

    L1SR_OBSCited in: Microbiology and Pathogenesis
  99. [99]

    Johansen ØH, Abdissa A, Zangenberg M et al.. “Performance and operational feasibility of two diagnostic tests for cryptosporidiosis in children (CRYPTO-POC): a clinical, prospective, diagnostic accuracy study.” The Lancet. Infectious diseases (2020). PMID: 33278916 ↗

    L2SR_OBSCited in: Microbiology and Pathogenesis
  100. [100]

    Modjarrad K, Vermund SH. “Effect of treating co-infections on HIV-1 viral load: a systematic review.” The Lancet. Infectious diseases (2010). PMID: 20610327 ↗

    L1SR_OBSCited in: Microbiology and Pathogenesis
  101. [101]

    Imperial MZ, Nedelman JR, Conradie F et al.. “Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34604901 ↗

    L4TRIAL_NONRANDOMCited in: Microbiology and Pathogenesis
  102. [102]

    Dooley KE, Rosenkranz SL, Conradie F et al.. “QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.” The Lancet. Infectious diseases (2021). PMID: 33587897 ↗

    L1RCTCited in: Microbiology and Pathogenesis
  103. [103]

    Gupte AN, Boisson-Walsh A, Huaman MA et al.. “Long-term Sequelae of Pulmonary Tuberculosis: A Narrative Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41974033 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, History and Evolution of Treatment, Complications, Prognosis and Natural History
  104. [104]

    Sun HY, Singh N. “Opportunistic infection-associated immune reconstitution syndrome in transplant recipients.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21690625 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  105. [105]

    Morrison VA. “Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 25352632 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  106. [106]

    Bobak CA, Botha M, Workman L et al.. “Gene Expression in Cord Blood and Tuberculosis in Early Childhood: A Nested Case-Control Study in a South African Birth Cohort.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37144357 ↗

    L3CASE_CONTROLCited in: Microbiology and Pathogenesis
  107. [107]

    Tenover FC. “Rapid detection and identification of bacterial pathogens using novel molecular technologies: infection control and beyond.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2006). PMID: 17205452 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  108. [108]

    Zumla A, Rao M, Wallis RS et al.. “Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.” The Lancet. Infectious diseases (2016). PMID: 27036359 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  109. [109]

    Kaufmann SH. “Fact and fiction in tuberculosis vaccine research: 10 years later.” The Lancet. Infectious diseases (2011). PMID: 21798463 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Prevention and Infection Control
  110. [110]

    Yansouni CP, Bottieau E, Lutumba P et al.. “Rapid diagnostic tests for neurological infections in central Africa.” The Lancet. Infectious diseases (2013). PMID: 23623369 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  111. [111]

    Drain PK, Bajema KL, Dowdy D et al.. “Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.” Clinical microbiology reviews (2018). PMID: 30021818 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  112. [112]

    Drancourt M, Michel-Lepage A, Boyer S et al.. “The Point-of-Care Laboratory in Clinical Microbiology.” Clinical microbiology reviews (2016). PMID: 27029593 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup
  113. [113]

    Trastoy R, Manso T, Fernández-García L et al.. “Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments.” Clinical microbiology reviews (2018). PMID: 30068737 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  114. [114]

    Sable SB, Posey JE, Scriba TJ. “Tuberculosis Vaccine Development: Progress in Clinical Evaluation.” Clinical microbiology reviews (2019). PMID: 31666281 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  115. [115]

    Mathema B, Kurepina NE, Bifani PJ et al.. “Molecular epidemiology of tuberculosis: current insights.” Clinical microbiology reviews (2006). PMID: 17041139 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors
  116. [116]

    Forbes BA, Hall GS, Miller MB et al.. “Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria.” Clinical microbiology reviews (2018). PMID: 29386234 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  117. [117]

    Warner DF, Mizrahi V. “Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy.” Clinical microbiology reviews (2006). PMID: 16847086 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  118. [118]

    Trauer JM, Dodd PJ, Gomes MGM et al.. “The Importance of Heterogeneity to the Epidemiology of Tuberculosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30383204 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  119. [119]

    Visser DH, Solomons RS, Ronacher K et al.. “Host immune response to tuberculous meningitis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 25301213 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  120. [120]

    Aguado JM, Torre-Cisneros J, Fortún J et al.. “Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19320593 ↗

    L1OTHERCited in: Microbiology and Pathogenesis
  121. [121]

    Moore CC, Jacob ST, Banura P et al.. “Etiology of Sepsis in Uganda Using a Quantitative Polymerase Chain Reaction-based TaqMan Array Card.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 29868873 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  122. [122]

    Rocco JM, Laidlaw E, Galindo F et al.. “Severe Mycobacterial Immune Reconstitution Inflammatory Syndrome (IRIS) in Advanced Human Immunodeficiency Virus (HIV) Has Features of Hemophagocytic Lymphohistiocytosis and Requires Prolonged Immune Suppression.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36048425 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  123. [123]

    Lawn SD, Zumla AI. “Tuberculosis.” Lancet (London, England) (2011). PMID: 21420161 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Special Hosts and Populations
  124. [124]

    Yew WW, Chang KC, Chan DP. “Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.” Antimicrobial agents and chemotherapy (2018). PMID: 29784840 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History, Special Hosts and Populations
  125. [125]

    Clerc O, Prod'hom G, Greub G et al.. “Adult native septic arthritis: a review of 10 years of experience and lessons for empirical antibiotic therapy.” The Journal of antimicrobial chemotherapy (2011). PMID: 21393124 ↗

    L4REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  126. [126]

    Dawson R, Diacon AH, Variava E et al.. “Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.” The Lancet. Infectious diseases (2026). PMID: 42214407 ↗

    L1OTHERCited in: Microbiology and Pathogenesis
  127. [127]

    Pavlovic F, Kwizera R, Denning DW. “Chronic Pulmonary Aspergillosis in Children: A Scoping Global Review.” Open forum infectious diseases (2026). PMID: 42095215 ↗

    L4REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Severity Assessment and Risk Stratification
  128. [128]

    Mangum L, Kilpatrick D, Stryjewska B et al.. “Tuberculosis and Leprosy Coinfection: A Perspective on Diagnosis and Treatment.” Open forum infectious diseases (2018). PMID: 30046638 ↗

    L4CASE_REPORTCited in: Microbiology and Pathogenesis
  129. [129]

    Chauhan U, Barth VC, Woychik NA. “tRNAfMet Inactivating Mycobacterium tuberculosis VapBC Toxin-Antitoxin Systems as Therapeutic Targets.” Antimicrobial agents and chemotherapy (2022). PMID: 35404073 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  130. [130]

    Zhang N, Strydom N, Tyagi S et al.. “Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.” Antimicrobial agents and chemotherapy (2020). PMID: 31907182 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Prevention and Infection Control
  131. [131]

    Vasil ML, Tomaras AP, Pritchard AE. “Identification and evaluation of twin-arginine translocase inhibitors.” Antimicrobial agents and chemotherapy (2012). PMID: 23006747 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  132. [132]

    Johnson BK, Colvin CJ, Needle DB et al.. “The Carbonic Anhydrase Inhibitor Ethoxzolamide Inhibits the Mycobacterium tuberculosis PhoPR Regulon and Esx-1 Secretion and Attenuates Virulence.” Antimicrobial agents and chemotherapy (2015). PMID: 25987613 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  133. [133]

    Shah S, Dalecki AG, Malalasekera AP et al.. “8-Hydroxyquinolines Are Boosting Agents of Copper-Related Toxicity in Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2016). PMID: 27431227 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  134. [134]

    Domenech P, Mouhoub E, Reed MB. “Experimental Confirmation that an Uncommon rrs Gene Mutation (g878a) of Mycobacterium tuberculosis Confers Resistance to Streptomycin.” Antimicrobial agents and chemotherapy (2022). PMID: 35072512 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  135. [135]

    Ordonez AA, Pokkali S, DeMarco VP et al.. “Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice.” Antimicrobial agents and chemotherapy (2014). PMID: 25403669 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  136. [136]

    Kidwai S, Bouzeyen R, Chakraborti S et al.. “NU-6027 Inhibits Growth of Mycobacterium tuberculosis by Targeting Protein Kinase D and Protein Kinase G.” Antimicrobial agents and chemotherapy (2019). PMID: 31285226 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  137. [137]

    Prosser GA, Rodenburg A, Khoury H et al.. “Glutamate Racemase Is the Primary Target of β-Chloro-d-Alanine in Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2016). PMID: 27480853 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  138. [138]

    Zimenkov DV, Kulagina EV, Antonova OV et al.. “Simultaneous drug resistance detection and genotyping of Mycobacterium tuberculosis using a low-density hydrogel microarray.” The Journal of antimicrobial chemotherapy (2016). PMID: 26929267 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation
  139. [139]

    Cheung CY, McNeil MB, Cook GM. “Utilization of CRISPR interference to investigate the contribution of genes to pathogenesis in a macrophage model of Mycobacterium tuberculosis infection.” The Journal of antimicrobial chemotherapy (2022). PMID: 34850009 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  140. [140]

    Isaeva Y, Bukatina A, Krylova L et al.. “Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system.” The Journal of antimicrobial chemotherapy (2013). PMID: 23788475 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  141. [141]

    Rv K, Asif N, Sethunath AN et al.. “Epigenetic Reprogramming by Mycobacterium tuberculosis Secretory Proteins: Implications for Pathogenesis and Therapy.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353681 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation
  142. [142]

    Liu H, Li P, He S et al.. “The role and mechanisms of multiple immunoregulatory cells in pulmonary tuberculosis.” Frontiers in immunology (2026). PMID: 42311673 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  143. [143]

    Mutavhatsindi H, Du Bruyn E, Ruzive S et al.. “Blood and Site of Disease Inflammatory Profiles Differ in Patients With Pericardial Tuberculosis and Human Immunodeficiency Virus Type 1.” Open forum infectious diseases (2023). PMID: 36998631 ↗

    L3OTHERCited in: Microbiology and Pathogenesis
  144. [144]

    Khambati N, Moureen KA, Basile FW et al.. “Oral Swab Testing With Xpert MTB/RIF Ultra for the Diagnosis of Tuberculosis in Children Aged <5 Years in Uganda: An Exploratory Interim Analysis of Diagnostic Accuracy in the NOD-pedFEND Cohort.” Open forum infectious diseases (2025). PMID: 40264985 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup
  145. [145]

    Jarchow-MacDonald A, Smith M, Seagar AL et al.. “Changing Incidence and Characteristics of Nontuberculous Mycobacterial Infections in Scotland and Comparison With Mycobacterium tuberculosis Complex Incidence (2011 to 2019).” Open forum infectious diseases (2022). PMID: 36726549 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  146. [146]

    Feria MG, Chang C, Ticona E et al.. “Pro-Inflammatory Alterations of Circulating Monocytes in Latent Tuberculosis Infection.” Open forum infectious diseases (2022). PMID: 36570965 ↗

    L3OTHERCited in: Microbiology and Pathogenesis
  147. [147]

    Schnittman SR, Byakwaga H, Boum Y et al.. “Changes in Immune Activation During Pregnancy and the Postpartum Period in Treated HIV Infection.” Open forum infectious diseases (2021). PMID: 34159218 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  148. [148]

    Huaman MA, Feria MG, Kendall MA et al.. “Monocyte Activation in People With HIV and Tuberculosis Coinfection and Effect of Tuberculosis Preventive Therapy: An Analysis of the ACTG A5279/BRIEF TB Trial.” Open forum infectious diseases (2025). PMID: 41488698 ↗

    L1OTHERCited in: Microbiology and Pathogenesis
  149. [149]

    Abelman RA, Fitzpatrick J, Byanova KL et al.. “Sex and HIV Differences in Preserved Ratio Impaired Spirometry (PRISm) Among Ugandans Postpneumonia.” Open forum infectious diseases (2024). PMID: 38456193 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  150. [150]

    Essone PN, Lotola-Mougeni F, Adegbite BR et al.. “Single and Combined Serum Proteins Expressed in TB Infection are Candidates for Point-of-care Diagnostic Testing of Active TB Patients in Lambaréné, Gabon.” Open forum infectious diseases (2024). PMID: 39108932 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  151. [151]

    Zeng W, Qiu Y, Tang S et al.. “Characterization of Anti-Interferon-γ Antibodies in HIV-Negative Patients Infected With Disseminated Talaromyces marneffei and Cryptococcosis.” Open forum infectious diseases (2019). PMID: 31660325 ↗

    L3OTHERCited in: Microbiology and Pathogenesis
  152. [152]

    Chernyaeva E, Rotkevich M, Krasheninnikova K et al.. “Whole-Genome Analysis of Mycobacterium tuberculosis from Patients with Tuberculous Spondylitis, Russia.” Emerging infectious diseases (2018). PMID: 29460750 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  153. [153]

    Liao TL, Lin CH, Shen GH et al.. “Risk for Mycobacterial Disease among Patients with Rheumatoid Arthritis, Taiwan, 2001-2011.” Emerging infectious diseases (2015). PMID: 26196158 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Severity Assessment and Risk Stratification
  154. [154]

    Castro KG, LoBue P. “Bridging implementation, knowledge, and ambition gaps to eliminate tuberculosis in the United States and globally.” Emerging infectious diseases (2011). PMID: 21392421 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  155. [155]

    Metcalfe JZ, Kim EY, Lin SY et al.. “Determinants of multidrug-resistant tuberculosis clusters, California, USA, 2004-2007.” Emerging infectious diseases (2010). PMID: 20735924 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  156. [156]

    Bonnar PE, Cunningham NP, Boggild AK et al.. “Leprosy in Nonimmigrant Canadian Man without Travel outside North America, 2014.” Emerging infectious diseases (2018). PMID: 29260666 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  157. [157]

    Miller MA, Buss P, Parsons SDC et al.. “Conservation of White Rhinoceroses Threatened by Bovine Tuberculosis, South Africa, 2016-2017.” Emerging infectious diseases (2018). PMID: 30457539 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  158. [158]

    Svensson E, Jensen ET, Rasmussen EM et al.. “Mycobacterium chimaera in Heater-Cooler Units in Denmark Related to Isolates from the United States and United Kingdom.” Emerging infectious diseases (2017). PMID: 28035898 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  159. [159]

    Li Y, Li J, Wang H et al.. “Ischial tuberculosis: MRI and mNGS enable early diagnosis in the largest reported case series of twenty two patients.” International orthopaedics (2026). PMID: 42410232 ↗

    L4CASE_REPORTCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  160. [160]

    Gupta S, Gupta S, Tyagi P et al.. “Maxillofacial tubercular osteomyelitis: diagnostic and therapeutic perspectives from a case series.” BMC infectious diseases (2026). PMID: 42316079 ↗

    L4CASE_REPORTCited in: Microbiology and Pathogenesis
  161. [161]

    Arrazuria R, Alonso-Hearn M, Juste RA et al.. “Advances in paratuberculosis research and control: a comprehensive expert review.” BMC veterinary research (2026). PMID: 42432668 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  162. [162]

    Kamal YA, Elkhayat H. “Pleural Tuberculosis.” Thoracic surgery clinics (2026). PMID: 42336509 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  163. [163]

    Sivasubramaniam P, Alagarsamy K, Michael MM et al.. “IgY technology (egg yolk antibodies) in respiratory medicine: applications and future prospects.” Archives of microbiology (2026). PMID: 42262426 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  164. [164]

    Tunesi S, Bothamley G, Günther G et al.. “A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2026 Update for Clinicians and Scientists.” Pathogens & immunity (2026). PMID: 42253400 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  165. [165]

    Aydemir S, Arziman S, Bozok V. “Immunoregulatory roles of microRNAs in bacterial infections: A focus on tuberculosis and sepsis.” Microbial pathogenesis (2026). PMID: 42217810 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  166. [166]

    Sundaram K, Rathinam S. “Extracellular Vesicles of Mycobacterium tuberculosis Serve as a Virulence Factor - Current Research Applications.” Current microbiology (2026). PMID: 42209895 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  167. [167]

    Mamudi C, Purnamawati, Andana P et al.. “RISK6 as a Translational Host Transcriptomic Signature for Tuberculosis Diagnosis, Treatment Monitoring, and Risk Stratification.” Pathogens (Basel, Switzerland) (2026). PMID: 42198615 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  168. [168]

    Lee MR, Huang YP, Kuo YT et al.. “Diabetes Mellitus and Latent Tuberculosis Infection: A Systematic Review and Metaanalysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 27986673 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Complications
  169. [169]

    Andrews JR, Noubary F, Walensky RP et al.. “Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2012). PMID: 22267721 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Complications
  170. [170]

    Igbokwe V, Ruby LC, Sultanli A et al.. “Post-tuberculosis sequelae in children and adolescents: a systematic review.” The Lancet. Infectious diseases (2023). PMID: 36963920 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Special Hosts and Populations
  171. [171]

    Olea-Popelka F, Muwonge A, Perera A et al.. “Zoonotic tuberculosis in human beings caused by Mycobacterium bovis-a call for action.” The Lancet. Infectious diseases (2016). PMID: 27697390 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup
  172. [172]

    Müller M, Wandel S, Colebunders R et al.. “Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2010). PMID: 20334848 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
  173. [173]

    Sengupta A, Ray A, Upadhyay AD et al.. “Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis.” The Lancet. Infectious diseases (2024). PMID: 39617023 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History
  174. [174]

    Mangione CM, Barry MJ, Nicholson WK et al.. “Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement.” JAMA (2023). PMID: 37129649 ↗

    L1GUIDELINECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications
  175. [175]

    Zhu Y, Forsman LD, Chen C et al.. “Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From China.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38913750 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  176. [176]

    Lee HR, Yoo JE, Choi H et al.. “Tuberculosis and the Risk of Ischemic Heart Disease: A Nationwide Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36519336 ↗

    L3COHORTCited in: Epidemiology, Transmission and Risk Factors, Complications
  177. [177]

    Ytterberg SR, Bhatt DL, Mikuls TR et al.. “Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.” The New England journal of medicine (2022). PMID: 35081280 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications
  178. [178]

    Conradie F, Bagdasaryan TR, Borisov S et al.. “Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.” The New England journal of medicine (2022). PMID: 36053506 ↗

    L4RCTCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  179. [179]

    Nyang'wa BT, Berry C, Kazounis E et al.. “A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.” The New England journal of medicine (2022). PMID: 36546625 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  180. [180]

    Fox GJ, Nhung NV, Cam Binh N et al.. “Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam.” The New England journal of medicine (2024). PMID: 39693541 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Special Hosts and Populations
  181. [181]

    Hesseling AC, Purchase SE, Martinson NA et al.. “Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis.” The New England journal of medicine (2024). PMID: 39693542 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Special Hosts and Populations
  182. [182]

    Cohen MS, Chen YQ, McCauley M et al.. “Prevention of HIV-1 infection with early antiretroviral therapy.” The New England journal of medicine (2011). PMID: 21767103 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Special Hosts and Populations
  183. [183]

    Tait DR, Hatherill M, Van Der Meeren O et al.. “Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.” The New England journal of medicine (2019). PMID: 31661198 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, History and Evolution of Treatment, Complications, Prevention and Infection Control
  184. [184]

    Schmidt AC, Fairlie L, Hellström E et al.. “BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.” The New England journal of medicine (2025). PMID: 40334156 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Special Hosts and Populations
  185. [185]

    Swindells S, Ramchandani R, Gupta A et al.. “One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.” The New England journal of medicine (2019). PMID: 30865794 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Special Hosts and Populations
  186. [186]

    . “Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.” Lancet (London, England) (2018). PMID: 30146330 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Prognosis and Natural History
  187. [187]

    Frascella B, Richards AS, Sossen B et al.. “Subclinical Tuberculosis Disease-A Review and Analysis of Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening Methodology.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32936877 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Special Hosts and Populations
  188. [188]

    Olotu AA, Bick JA, Medley-Lane BS et al.. “Infection Control in Carceral Facilities.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41117671 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Prevention and Infection Control
  189. [189]

    Deiss RG, Rodwell TC, Garfein RS. “Tuberculosis and illicit drug use: review and update.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19046064 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  190. [190]

    Conradie F, Diacon AH, Ngubane N et al.. “Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.” The New England journal of medicine (2020). PMID: 32130813 ↗

    L4TRIAL_NONRANDOMCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  191. [191]

    Jonas DE, Riley SR, Lee LC et al.. “Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2023). PMID: 37129650 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  192. [192]

    Pasipanodya JG, Ogbonna D, Ferro BE et al.. “Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.” Antimicrobial agents and chemotherapy (2017). PMID: 28807911 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  193. [193]

    Xu HB, Jiang RH, Li L. “Pulmonary resection for patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.” The Journal of antimicrobial chemotherapy (2011). PMID: 21642292 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  194. [194]

    Korotych O, Achar J, Gurbanova E et al.. “Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.” The Lancet. Infectious diseases (2024). PMID: 38880112 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History, Special Hosts and Populations
  195. [195]

    Zahid M, Rahman F, Danaee M et al.. “An mHealth (Mobile Health) Intervention for Smoking Cessation in People With Tuberculosis: A Cluster Randomized Clinical Trial.” JAMA (2026). PMID: 41428342 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  196. [196]

    Bergeron A, Mikulska M, De Greef J et al.. “Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia.” The Lancet. Infectious diseases (2022). PMID: 35636446 ↗

    L1REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  197. [197]

    Teicher A. “Super-spreaders: a historical review.” The Lancet. Infectious diseases (2023). PMID: 37352877 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Special Hosts and Populations
  198. [198]

    Nguyen MH, Wong G, Gane E et al.. “Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.” Clinical microbiology reviews (2020). PMID: 32102898 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History
  199. [199]

    Gal-Mor O. “Persistent Infection and Long-Term Carriage of Typhoidal and Nontyphoidal Salmonellae.” Clinical microbiology reviews (2018). PMID: 30487167 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  200. [200]

    Kwan CK, Ernst JD. “HIV and tuberculosis: a deadly human syndemic.” Clinical microbiology reviews (2011). PMID: 21482729 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Special Hosts and Populations
  201. [201]

    Ibrahim MK, Zambruni M, Melby CL et al.. “Impact of Childhood Malnutrition on Host Defense and Infection.” Clinical microbiology reviews (2017). PMID: 28768707 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors
  202. [202]

    Yapa HM, MacLean EL-H, Menzies NA et al.. “Drug-resistant tuberculosis: a priority pathogen for enhanced public health research and practice.” Clinical microbiology reviews (2025). PMID: 41186421 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  203. [203]

    Dookie N, Ngema SL, Perumal R et al.. “The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives.” Clinical microbiology reviews (2022). PMID: 36200885 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  204. [204]

    van Hal SJ, Jensen SO, Vaska VL et al.. “Predictors of mortality in Staphylococcus aureus Bacteremia.” Clinical microbiology reviews (2012). PMID: 22491776 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  205. [205]

    Nguyen HV, Tiemersma E, Nguyen NV et al.. “Disease Transmission by Patients With Subclinical Tuberculosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36660850 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors
  206. [206]

    Fei ZT, Xia L, Yang Y et al.. “Incidence and Risk Factors of Ophthalmic Nerve Palsy in Patients With Tuberculous Meningitis: A Retrospective Study and Literature Review.” Open forum infectious diseases (2024). PMID: 39665113 ↗

    L4TRIAL_NONRANDOMCited in: Epidemiology, Transmission and Risk Factors
  207. [207]

    Coelho LE, Chazallon C, Laureillard D et al.. “Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial.” Open forum infectious diseases (2024). PMID: 38486816 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology, Transmission and Risk Factors
  208. [208]

    Veve MP, Kenney RM, Aljundi AM et al.. “Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States.” Antimicrobial agents and chemotherapy (2025). PMID: 40035548 ↗

    L4COHORTCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History, Special Hosts and Populations
  209. [209]

    Wasserman S, Brust JCM, Abdelwahab MT et al.. “Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study.” The Journal of antimicrobial chemotherapy (2022). PMID: 35134182 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Special Hosts and Populations
  210. [210]

    Chien JY, Chien ST, Huang SY et al.. “Safety of rifabutin replacing rifampicin in the treatment of tuberculosis: a single-centre retrospective cohort study.” The Journal of antimicrobial chemotherapy (2013). PMID: 24243988 ↗

    L4COHORTCited in: Epidemiology, Transmission and Risk Factors, Complications
  211. [211]

    Trajman A, Campbell JR, Kunor T et al.. “Tuberculosis.” Lancet (London, England) (2025). PMID: 40057344 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications, Special Hosts and Populations
  212. [212]

    Furin J, Cox H, Pai M. “Tuberculosis.” Lancet (London, England) (2019). PMID: 30904262 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  213. [213]

    Dheda K, Barry CE, Maartens G. “Tuberculosis.” Lancet (London, England) (2015). PMID: 26377143 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  214. [214]

    Lange C, Dheda K, Chesov D et al.. “Management of drug-resistant tuberculosis.” Lancet (London, England) (2019). PMID: 31526739 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  215. [215]

    Salvi SS, Barnes PJ. “Chronic obstructive pulmonary disease in non-smokers.” Lancet (London, England) (2009). PMID: 19716966 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, History and Evolution of Treatment, Complications
  216. [216]

    Prince M, Patel V, Saxena S et al.. “No health without mental health.” Lancet (London, England) (2007). PMID: 17804063 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History, Special Hosts and Populations
  217. [217]

    Chen X, Giles J, Yao Y et al.. “The path to healthy ageing in China: a Peking University-Lancet Commission.” Lancet (London, England) (2022). PMID: 36423650 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors
  218. [218]

    Uden L, Barber E, Ford N et al.. “Risk of Tuberculosis Infection and Disease for Health Care Workers: An Updated Meta-Analysis.” Open forum infectious diseases (2017). PMID: 28875155 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  219. [219]

    Ravi D, Yusof NY, Salleh MZ et al.. “Prevalence of extensively drug-resistant tuberculosis and drug resistance patterns in Asia and Africa (2000-2025): systematic review and meta-analysis.” Infection (2026). PMID: 42430119 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  220. [220]

    Kennard A, Kılıç A, Alsugeir D et al.. “A systematic review of the determinants of vaccine hesitancy in the UK: Implications for future TB vaccine adoption.” BMC public health (2026). PMID: 42374300 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  221. [221]

    Alanazi R, Alghamdi H, Alansari R et al.. “Epidemiology and risk factors of multidrug-resistant tuberculosis in Saudi Arabia: a systematic review and meta-analysis.” Frontiers in public health (2026). PMID: 42368954 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  222. [222]

    Korkosz R, Trzcionka A, Deręgowski R et al.. “Epidemiology of tuberculosis, scabies, and enteric infections in Polish prisons (2002-2023): A nationwide data analysis and systematic review.” Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2026). PMID: 42335388 ↗

    L4SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  223. [223]

    Waller KMJ, De La Mata NL, Wyburn KR et al.. “Notifiable Infectious Diseases Among Organ Transplant Recipients: A Data-Linked Cohort Study, 2000-2015.” Open forum infectious diseases (2022). PMID: 35937651 ↗

    L4COHORTCited in: Epidemiology, Transmission and Risk Factors, Prevention and Infection Control
  224. [224]

    Hamijoyo L, Sahiratmadja E, Ghassani NG et al.. “Tuberculosis Among Patients With Systemic Lupus Erythematosus in Indonesia: A Cohort Study.” Open forum infectious diseases (2022). PMID: 35794932 ↗

    L4COHORTCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  225. [225]

    Cremer PC, Klein AL, Imazio M. “Diagnosis, Risk Stratification, and Treatment of Pericarditis: A Review.” JAMA (2024). PMID: 39235771 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History
  226. [226]

    Barker AF, Karamooz E. “Non-Cystic Fibrosis Bronchiectasis in Adults: A Review.” JAMA (2025). PMID: 40293759 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications
  227. [227]

    Takiff H, Guerrero E. “Current prospects for the fluoroquinolones as first-line tuberculosis therapy.” Antimicrobial agents and chemotherapy (2011). PMID: 21876059 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors
  228. [228]

    Andrade RJ, Tulkens PM. “Hepatic safety of antibiotics used in primary care.” The Journal of antimicrobial chemotherapy (2011). PMID: 21586591 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Complications
  229. [229]

    Mejia-Chew C, Chavez MA, Lian M et al.. “Spatial Epidemiologic Analysis and Risk Factors for Nontuberculous Mycobacteria Infections, Missouri, USA, 2008-2019.” Emerging infectious diseases (2023). PMID: 37486160 ↗

    L3REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors
  230. [230]

    Dirlikov E, Thomas D, Yost D et al.. “Tuberculosis Surveillance and Control, Puerto Rico, 1898-2015.” Emerging infectious diseases (2019). PMID: 37933081 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment
  231. [231]

    Gorvetzian S, Pacheco AG, Anderson E et al.. “Mortality Rates after Tuberculosis Treatment, Georgia, USA, 2008-2019.” Emerging infectious diseases (2024). PMID: 39447141 ↗

    L3REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History, Special Hosts and Populations
  232. [232]

    Alahmari H, Hanson L, Kelley PG et al.. “Interferon-Gamma Release Assays versus Tuberculin Skin Test for latent tuberculosis infection positivity among healthcare workers and first responders: a systematic review and meta-analysis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42398701 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prevention and Infection Control
  233. [233]

    . “Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.” Lancet (London, England) (2024). PMID: 38582094 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History, Special Hosts and Populations
  234. [234]

    Zeng BS, Lo WC, Ho CC et al.. “Ambient air pollution and risk of active tuberculosis: a population-based cohort study in Taiwan.” International journal of epidemiology (2026). PMID: 42406782 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment
  235. [235]

    Yang H, Zhang Y, Xu H et al.. “Drug-resistant tuberculosis in Lishui, China: first-line drug resistance patterns, trends, and risk factors from a 10-year retrospective study (2015-2024).” Frontiers in public health (2026). PMID: 42388770 ↗

    L3COHORTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  236. [236]

    Saksaen P, Boonchieng E, Thongprachum A et al.. “Predicting Tuberculosis Outcomes Using Routine Surveillance Data in Chiang Mai, Thailand: Retrospective Cohort Study.” JMIR public health and surveillance (2026). PMID: 42348883 ↗

    L3COHORTCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History, Special Hosts and Populations
  237. [237]

    Ye X, Le S, Han S et al.. “Risk Factors and Prediction of Chronic Obstructive Pulmonary Disease After Pulmonary Tuberculosis: A Prospective Cohort Study.” International journal of chronic obstructive pulmonary disease (2026). PMID: 42328419 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  238. [238]

    El Bcheraoui C, Mokdad AH, Dwyer-Lindgren L et al.. “Trends and Patterns of Differences in Infectious Disease Mortality Among US Counties, 1980-2014.” JAMA (2018). PMID: 29584843 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History, Special Hosts and Populations
  239. [239]

    Cain KP, Benoit SR, Winston CA et al.. “Tuberculosis among foreign-born persons in the United States.” JAMA (2008). PMID: 18647983 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  240. [240]

    Gona P, Van Dyke RB, Williams PL et al.. “Incidence of opportunistic and other infections in HIV-infected children in the HAART era.” JAMA (2006). PMID: 16849662 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History, Special Hosts and Populations
  241. [241]

    Wang F, Shao L, Fan X et al.. “Evolution and transmission patterns of extensively drug-resistant tuberculosis in China.” Antimicrobial agents and chemotherapy (2014). PMID: 25403663 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment
  242. [242]

    Huyen MN, Cobelens FG, Buu TN et al.. “Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes.” Antimicrobial agents and chemotherapy (2013). PMID: 23689727 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  243. [243]

    Arnold A, Cooke GS, Kon OM et al.. “Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.” Antimicrobial agents and chemotherapy (2017). PMID: 28696239 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors
  244. [244]

    Aguilar-Pérez C, Gracia B, Rodrigues L et al.. “Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2018). PMID: 29987141 ↗

    L5OTHERCited in: Epidemiology, Transmission and Risk Factors
  245. [245]

    Chien JY, Chiu WY, Chien ST et al.. “Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.” Antimicrobial agents and chemotherapy (2016). PMID: 26787695 ↗

    L5OTHERCited in: Epidemiology, Transmission and Risk Factors
  246. [246]

    Narmandakh E, Tumenbayar O, Borolzoi T et al.. “Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia.” Antimicrobial agents and chemotherapy (2020). PMID: 32312782 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors
  247. [247]

    Lopez B, Siqueira de Oliveira R, Pinhata JMW et al.. “Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region.” The Journal of antimicrobial chemotherapy (2019). PMID: 30358851 ↗

    L5OTHERCited in: Epidemiology, Transmission and Risk Factors
  248. [248]

    Mok S, Roycroft E, Flanagan PR et al.. “Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.” The Journal of antimicrobial chemotherapy (2023). PMID: 37740935 ↗

    L5OTHERCited in: Epidemiology, Transmission and Risk Factors
  249. [249]

    Jajou R, van der Laan T, de Zwaan R et al.. “WGS more accurately predicts susceptibility of Mycobacterium tuberculosis to first-line drugs than phenotypic testing.” The Journal of antimicrobial chemotherapy (2019). PMID: 31119271 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors
  250. [250]

    Vyazovaya A, Levina K, Zhuravlev V et al.. “Emerging resistant clones of Mycobacterium tuberculosis in a spatiotemporal context.” The Journal of antimicrobial chemotherapy (2018). PMID: 29092043 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors
  251. [251]

    Yew WW, Leung CC, Zhang Y. “Oxidative stress and TB outcomes in patients with diabetes mellitus?” The Journal of antimicrobial chemotherapy (2017). PMID: 28204508 ↗

    L5OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  252. [252]

    Kang SW, Jang HM, Chang E et al.. “Impact of fluoroquinolone exposure on the diagnosis and prognosis of tuberculosis in immunocompromised patients: a propensity-score-matched, competing risk analysis.” The Journal of antimicrobial chemotherapy (2025). PMID: 40192420 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Severity Assessment and Risk Stratification, Prognosis and Natural History
  253. [253]

    Kyaw NTT, Silin M, Trieu L et al.. “Tuberculosis Incidence and Outcomes Among Older New Yorkers.” Open forum infectious diseases (2025). PMID: 40151484 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  254. [254]

    Båtshake Y, Walles J, Winqvist N et al.. “Tuberculosis Infection and Disease Among Pregnant People Living in Sweden With Origin in Tuberculosis-Endemic Countries.” Open forum infectious diseases (2023). PMID: 37520421 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Special Hosts and Populations
  255. [255]

    O'Connell J, Reidy N, McNally C et al.. “Delayed Tuberculosis Treatment and Cost of Care in a Low-Incidence Country.” Open forum infectious diseases (2022). PMID: 35611347 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Empiric Management, Acute Care and Source Control
  256. [256]

    Buziashvili M, Djibuti M, Tukvadze N et al.. “Incidence Rate and Risk Factors for Developing Active Tuberculosis Among People Living With HIV in Georgia 2019-2020 Cohort.” Open forum infectious diseases (2024). PMID: 39257676 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  257. [257]

    Huang W, Fei Z, Yan B et al.. “Risk Factors for Disseminated Tuberculosis and Associated Survival in Adults Without Human Immunodeficiency Virus.” Open forum infectious diseases (2024). PMID: 39817036 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  258. [258]

    Noroc E, Chesov D, Merker M et al.. “Limited Nosocomial Transmission of Drug-Resistant Tuberculosis, Moldova.” Emerging infectious diseases (2023). PMID: 37081601 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  259. [259]

    Humayun M, Mukasa L, Ye W et al.. “Racial and Ethnic Disparities in Tuberculosis Incidence, Arkansas, USA, 2010-2021.” Emerging infectious diseases (2024). PMID: 38146997 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  260. [260]

    Martinez L, Cords O, Horsburgh CR et al.. “The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis.” Lancet (London, England) (2020). PMID: 32199484 ↗

    L2SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Prevention and Infection Control, Special Hosts and Populations
  261. [261]

    Swaminathan S, Padmapriyadarsini C, Narendran G. “HIV-associated tuberculosis: clinical update.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20388036 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  262. [262]

    Swaminathan S, Rekha B. “Pediatric tuberculosis: global overview and challenges.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20397947 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Complications
  263. [263]

    Bhargava A, Bhargava M, Meher A et al.. “Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial.” Lancet (London, England) (2023). PMID: 37567200 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History
  264. [264]

    Kahwati LC, Feltner C, Halpern M et al.. “Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2016). PMID: 27599332 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  265. [265]

    Valafar SJ. “Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2021). PMID: 33361298 ↗

    L2SR_OBSCited in: Clinical Presentation, History and Evolution of Treatment
  266. [266]

    Whitfield MG, Warren RM, Mathys V et al.. “The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.” The Journal of antimicrobial chemotherapy (2018). PMID: 29982641 ↗

    L4SR_OBSCited in: Clinical Presentation, Diagnosis and Workup
  267. [267]

    Chang KC, Yew WW, Chan RC. “Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.” The Journal of antimicrobial chemotherapy (2010). PMID: 20542907 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  268. [268]

    Brastianos PK, Swanson JW, Torbenson M et al.. “Tuberculosis-associated haemophagocytic syndrome.” The Lancet. Infectious diseases (2006). PMID: 16790385 ↗

    L5CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup, Complications
  269. [269]

    Genovese MC, Kalunian K, Gottenberg JE et al.. “Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.” JAMA (2019). PMID: 31334793 ↗

    L1RCTCited in: Clinical Presentation, Severity Assessment and Risk Stratification, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications
  270. [270]

    Furin JJ, Du Bois J, van Brakel E et al.. “Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.” Antimicrobial agents and chemotherapy (2016). PMID: 27550361 ↗

    L1RCTCited in: Clinical Presentation
  271. [271]

    Tirlangi PK, Pothumarthy VSK, Khan AR et al.. “Mycobacterial Infections in Patients With Hairy Cell Leukemia: A Systematic Review of Published Cases.” Open forum infectious diseases (2026). PMID: 41716680 ↗

    L4SR_OBSCited in: Clinical Presentation
  272. [272]

    Collin SM, Lima A, Heringer S et al.. “Systematic Review of Hansen Disease Attributed to Mycobacterium lepromatosis.” Emerging infectious diseases (2023). PMID: 37347507 ↗

    L4SR_OBSCited in: Clinical Presentation, Diagnosis and Workup
  273. [273]

    Hopewell PC, Pai M, Maher D et al.. “International standards for tuberculosis care.” The Lancet. Infectious diseases (2006). PMID: 17067920 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Complications, Special Hosts and Populations
  274. [274]

    Walzl G, McNerney R, du Plessis N et al.. “Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.” The Lancet. Infectious diseases (2018). PMID: 29580818 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup
  275. [275]

    Li H, Salinger DH, Everitt D et al.. “Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.” Antimicrobial agents and chemotherapy (2019). PMID: 31358590 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation
  276. [276]

    Moultrie H, McIlleron H, Sawry S et al.. “Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.” The Journal of antimicrobial chemotherapy (2014). PMID: 25281400 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Complications, Special Hosts and Populations
  277. [277]

    Zak DE, Penn-Nicholson A, Scriba TJ et al.. “A blood RNA signature for tuberculosis disease risk: a prospective cohort study.” Lancet (London, England) (2016). PMID: 27017310 ↗

    L2COHORTCited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Special Hosts and Populations
  278. [278]

    Luies L, du Preez I. “The Echo of Pulmonary Tuberculosis: Mechanisms of Clinical Symptoms and Other Disease-Induced Systemic Complications.” Clinical microbiology reviews (2020). PMID: 32611585 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History
  279. [279]

    Heyckendorf J, Georghiou SB, Frahm N et al.. “Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.” Clinical microbiology reviews (2022). PMID: 35311552 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  280. [280]

    Saccente M, Woods GL. “Clinical and laboratory update on blastomycosis.” Clinical microbiology reviews (2010). PMID: 20375357 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  281. [281]

    Schito M, Migliori GB, Fletcher HA et al.. “Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26409271 ↗

    L5OTHERCited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  282. [282]

    Davis AG, Dreyer AJ, Albertyn C et al.. “Cognitive Impairment in Tuberculous Meningitis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36262054 ↗

    L4OTHERCited in: Clinical Presentation, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations
  283. [283]

    Miao Q, Ma Y, Wang Q et al.. “Microbiological Diagnostic Performance of Metagenomic Next-generation Sequencing When Applied to Clinical Practice.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 30423048 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control
  284. [284]

    Kim SH, Kim MY, Hong SI et al.. “Invasive Pulmonary Aspergillosis-mimicking Tuberculosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 25778752 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup, Special Hosts and Populations
  285. [285]

    Reuter A, Hughes J, Furin J. “Challenges and controversies in childhood tuberculosis.” Lancet (London, England) (2019). PMID: 31526740 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Prevention and Infection Control
  286. [286]

    Rubenstein LS, Amon JJ, McLemore M et al.. “HIV, prisoners, and human rights.” Lancet (London, England) (2016). PMID: 27427457 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup
  287. [287]

    Kibirige D, Owarwo N, Kyazze AP et al.. “Prevalence, Clinical Features, and Predictors of Adrenal Insufficiency in Adults With Tuberculosis or HIV: A Systematic Review and Meta-analysis.” Open forum infectious diseases (2024). PMID: 38560601 ↗

    L1SR_OBSCited in: Clinical Presentation
  288. [288]

    Xu J, Kathiresan T, Siddiqui A et al.. “Cough biomarkers for diagnosis and monitoring of respiratory disease: a systematic review.” European respiratory review : an official journal of the European Respiratory Society (2026). PMID: 42342266 ↗

    L2SR_OBSCited in: Clinical Presentation
  289. [289]

    Martínez-Planas A, Baquero-Artigao F, Méndez-Echevarría A et al.. “A 28-Year Multicenter Cohort Study of Nontuberculous Mycobacterial Lymphadenitis in Children, Spain.” Emerging infectious diseases (2025). PMID: 40023802 ↗

    L2COHORTCited in: Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Special Hosts and Populations
  290. [290]

    Vaidya A, Findling J, Bancos I. “Adrenal Insufficiency in Adults: A Review.” JAMA (2025). PMID: 40522647 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications
  291. [291]

    Sethi D, Iyer TR, Abu-Al-Timen S. “Predictors of Recurrence Following Bronchial Artery Embolisation (BAE) for Haemoptysis: A Systematic Review and Evidence Synthesis Analyses Using SWiM Guidelines.” Cardiovascular and interventional radiology (2026). PMID: 42414635 ↗

    L2SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Complications
  292. [292]

    Baker J, Kosmidis C, Rozaliyani A et al.. “Chronic Pulmonary Histoplasmosis-A Scoping Literature Review.” Open forum infectious diseases (2020). PMID: 32411810 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Prognosis and Natural History
  293. [293]

    Goldberg DW, Tenforde MW, Mitchell HK et al.. “Neurological Sequelae of Adult Meningitis in Africa: A Systematic Literature Review.” Open forum infectious diseases (2017). PMID: 29322063 ↗

    L2REVIEW_NARRATIVECited in: Clinical Presentation, Complications, Special Hosts and Populations
  294. [294]

    Sane Schepisi M, Navarra A, Altet Gomez MN et al.. “Burden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study.” Open forum infectious diseases (2018). PMID: 30697572 ↗

    L3CASE_CONTROLCited in: Clinical Presentation
  295. [295]

    Kim M, Abu Saleh OM, Castillo Almeida NE et al.. “Clinical Presentation, Management, and Outcomes of Mycobacterium Bovis Bacillus Calmette-Guérin (BCG) Infections: A Single-center Retrospective Review.” Open forum infectious diseases (2026). PMID: 41799262 ↗

    L4REVIEW_NARRATIVECited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  296. [296]

    Miyahara R, Piboonsiri P, Chiyasirinroje B et al.. “Risk for Prison-to-Community Tuberculosis Transmission, Thailand, 2017-2020.” Emerging infectious diseases (2023). PMID: 36823074 ↗

    L2REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup
  297. [297]

    Denning DW, Perlin DS, Muldoon EG et al.. “Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic Capabilities.” Emerging infectious diseases (2017). PMID: 27997332 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Complications, Prognosis and Natural History
  298. [298]

    Outhred AC, Jelfs P, Suliman B et al.. “Added value of whole-genome sequencing for management of highly drug-resistant TB.” The Journal of antimicrobial chemotherapy (2014). PMID: 25492392 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  299. [299]

    Christian E, Johnston A. “CNS TB-IRIS Following Cessation of Adalimumab in an Adolescent With Crohn's Disease.” Open forum infectious diseases (2022). PMID: 35949406 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  300. [300]

    Lee JY, Lee HJ, Kim YK et al.. “Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients.” Antimicrobial agents and chemotherapy (2016). PMID: 27090178 ↗

    L3OTHERCited in: Clinical Presentation
  301. [301]

    Zhang D, Gomez JE, Chien JY et al.. “Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis.” Antimicrobial agents and chemotherapy (2016). PMID: 27572408 ↗

    L4OTHERCited in: Clinical Presentation
  302. [302]

    Medellín-Garibay SE, Cortez-Espinosa N, Milán-Segovia RC et al.. “Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters.” Antimicrobial agents and chemotherapy (2015). PMID: 26438503 ↗

    L4OTHERCited in: Clinical Presentation
  303. [303]

    Modongo C, Pasipanodya JG, Zetola NM et al.. “Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients.” Antimicrobial agents and chemotherapy (2015). PMID: 26248372 ↗

    L4OTHERCited in: Clinical Presentation
  304. [304]

    Xie YL, Modi N, Handler D et al.. “Simplified urine-based method to detect rifampin underexposure in adults with tuberculosis: a prospective diagnostic accuracy study.” Antimicrobial agents and chemotherapy (2023). PMID: 37877727 ↗

    L2OTHERCited in: Clinical Presentation
  305. [305]

    Ardizzoni E, Ariza E, Mulengwa D et al.. “Thin-Layer-Agar-Based Direct Phenotypic Drug Susceptibility Testing on Sputum in Eswatini Rapidly Detects Mycobacterium tuberculosis Growth and Rifampicin Resistance Otherwise Missed by WHO-Endorsed Diagnostic Tests.” Antimicrobial agents and chemotherapy (2021). PMID: 33722892 ↗

    L4OTHERCited in: Clinical Presentation
  306. [306]

    Ghebrekristos Y, Ahmed A, Beylis N et al.. “Xpert MTB/RIF Ultra-resistant and MTBDRplus-susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing.” Antimicrobial agents and chemotherapy (2025). PMID: 39918315 ↗

    L4OTHERCited in: Clinical Presentation
  307. [307]

    Ho J, Jelfs P, Sintchencko V. “Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment.” The Journal of antimicrobial chemotherapy (2013). PMID: 23838950 ↗

    L4OTHERCited in: Clinical Presentation
  308. [308]

    Van Rie A, Whitfield MG, De Vos E et al.. “Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact.” The Journal of antimicrobial chemotherapy (2020). PMID: 32016320 ↗

    L2OTHERCited in: Clinical Presentation
  309. [309]

    Prahl JB, Johansen IS, Cohen AS et al.. “Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.” The Journal of antimicrobial chemotherapy (2014). PMID: 25140577 ↗

    L2OTHERCited in: Clinical Presentation
  310. [310]

    Wu X, Lu W, Shao Y et al.. “The indirect microscopic observation drug susceptibility assay demonstrated high concordance with the indirect MGIT method for pyrazinamide susceptibility testing.” The Journal of antimicrobial chemotherapy (2015). PMID: 25953803 ↗

    L4OTHERCited in: Clinical Presentation
  311. [311]

    Khaba MC, Dikotope M, Nkwagatse T et al.. “Patterns of Infectious Disease Identified in Clinical Autopsy at a South African Tertiary Care Setting: A 10-Year Retrospective Study.” Diseases (Basel, Switzerland) (2026). PMID: 42346313 ↗

    L4COHORTCited in: Clinical Presentation, Special Hosts and Populations
  312. [312]

    Njagi LN, Tram KH, Zifodya JS et al.. “Pulmonary Tuberculosis Infectiousness of Persons Identified Through Active and Passive Case-finding in a High-burden Setting.” Open forum infectious diseases (2025). PMID: 40046891 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis and Workup, Special Hosts and Populations
  313. [313]

    Alsaeed M, Alanazi K, Alhamdan A et al.. “Exploring Mycobacterium riyadhense: Epidemiology, Clinical Presentation, and Treatment Outcome.” Open forum infectious diseases (2025). PMID: 40860514 ↗

    L4OTHERCited in: Clinical Presentation
  314. [314]

    Cardona-Castro N, Escobar-Builes MV, Serrano-Coll H et al.. “Mycobacterium lepromatosis as Cause of Leprosy, Colombia.” Emerging infectious diseases (2022). PMID: 35450566 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis and Workup
  315. [315]

    Dean SG, Ricotta EE, Fintzi J et al.. “Mycobacterial Testing Trends, United States, 2009-20151.” Emerging infectious diseases (2020). PMID: 32818422 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup
  316. [316]

    Yaidoo S, Yelbert JMT, MacScott-Lutterodt R et al.. “Integrated management of multidrug-resistant tuberculosis, HIV, and hepatitis B co-infection in Ghana: a case report.” Frontiers in medicine (2026). PMID: 42375210 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Antimicrobial Resistance and Stewardship
  317. [317]

    Ye Z, Ma LT, Wang S et al.. “Coexistence of papulonecrotic tuberculid and Poncet's disease: A case report of dual tuberculin hypersensitivity reactions and literature review.” Medicine (2026). PMID: 42363449 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  318. [318]

    Liu Y, Huang K, Lin F et al.. “Awareness and acceptance of latent tuberculosis infection screening and preventive treatment among healthcare workers: a cross-sectional study in Chongqing, China.” Frontiers in public health (2026). PMID: 42422702 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis and Workup
  319. [319]

    Mwau M, Karichu JK, Inziani M et al.. “Leveraging existing high-throughput HIV platforms for molecular Mycobacterium tuberculosis testing in Busia, Kenya: Cost and operational insights.” Journal of medical economics (2026). PMID: 42421287 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis and Workup
  320. [320]

    Ramos-Silva A, de Oliveira LST, da Costa MDS et al.. “Decline in Calmette-Guérin Bacillus Vaccination Coverage and Change in the Spatiotemporal Pattern of Extrapulmonary Tuberculosis in Children and Adolescents in Brazil: An Ecological Study, 2004-2023.” Tropical medicine & international health : TM & IH (2026). PMID: 42415597 ↗

    L2OTHERCited in: Clinical Presentation
  321. [321]

    Huang D, Chen M, Wu Q et al.. “From immunoinformatics insights to assay development: establishment of a peptide-based indirect elisa for cynomolgus tuberculosis detection.” Frontiers in cellular and infection microbiology (2026). PMID: 42404765 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis and Workup
  322. [322]

    Dorman SE, Nahid P, Kurbatova EV et al.. “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.” The New England journal of medicine (2021). PMID: 33951360 ↗

    L1RCTCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Hosts and Populations
  323. [323]

    Chang KC, Yew WW, Zhang Y. “Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.” Antimicrobial agents and chemotherapy (2011). PMID: 21768515 ↗

    L1SR_OBSCited in: Diagnosis and Workup
  324. [324]

    Kadura S, King N, Nakhoul M et al.. “Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.” The Journal of antimicrobial chemotherapy (2020). PMID: 32361756 ↗

    L2SR_OBSCited in: Diagnosis and Workup, History and Evolution of Treatment
  325. [325]

    Martin A, Portaels F, Palomino JC. “Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.” The Journal of antimicrobial chemotherapy (2006). PMID: 17135182 ↗

    L1SR_OBSCited in: Diagnosis and Workup
  326. [326]

    Vargas DA, Fuertes-Bucheli JF, Sanchez-Hidalgo A et al.. “Diagnostic Accuracy of Molecular Testing on Saliva and Oral Swabs for Pulmonary Tuberculosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41817395 ↗

    L3OTHERCited in: Diagnosis and Workup
  327. [327]

    Farhat MR, Jacobson KR. “For Tuberculosis, Not "To Screen or Not to Screen?" but "Who?" and "How?".” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38636953 ↗

    L5OTHERCited in: Diagnosis and Workup
  328. [328]

    Nguyen TVA, Anthony RM, Cao TTH et al.. “Delamanid Resistance: Update and Clinical Management.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 32521000 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  329. [329]

    Munsiff SS, Kambili C, Ahuja SD. “Rifapentine for the treatment of pulmonary tuberculosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2006). PMID: 17083024 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  330. [330]

    Jacob JT, Nguyen TM, Ray SM. “Male genital tuberculosis.” The Lancet. Infectious diseases (2008). PMID: 18471778 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  331. [331]

    Dorman SE, Schumacher SG, Alland D et al.. “Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study.” The Lancet. Infectious diseases (2017). PMID: 29198911 ↗

    L2OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control
  332. [332]

    Colman RE, Seifert M, De la Rossa A et al.. “Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows.” The Lancet. Infectious diseases (2024). PMID: 39486428 ↗

    L2OTHERCited in: Diagnosis and Workup
  333. [333]

    Parsons LM, Somoskövi A, Gutierrez C et al.. “Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities.” Clinical microbiology reviews (2011). PMID: 21482728 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Special Hosts and Populations
  334. [334]

    Pai M, Denkinger CM, Kik SV et al.. “Gamma interferon release assays for detection of Mycobacterium tuberculosis infection.” Clinical microbiology reviews (2014). PMID: 24396134 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup
  335. [335]

    Gordin FM, Masur H. “Current approaches to tuberculosis in the United States.” JAMA (2012). PMID: 22797646 ↗

    L5CASE_REPORTCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  336. [336]

    Rangaka MX, Cavalcante SC, Marais BJ et al.. “Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection.” Lancet (London, England) (2015). PMID: 26515679 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  337. [337]

    Telisinghe L, Charalambous S, Topp SM et al.. “HIV and tuberculosis in prisons in sub-Saharan Africa.” Lancet (London, England) (2016). PMID: 27427448 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  338. [338]

    Wallis RS, Pai M, Menzies D et al.. “Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice.” Lancet (London, England) (2010). PMID: 20488517 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  339. [339]

    Harries AD, Zachariah R, Corbett EL et al.. “The HIV-associated tuberculosis epidemic--when will we act?” Lancet (London, England) (2010). PMID: 20488516 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Prevention and Infection Control
  340. [340]

    Vega P, Newby R, Bender Ignacio RA et al.. “Donor-Derived Tuberculosis in 3 Solid Organ Transplant Recipients From the Same Donor.” Open forum infectious diseases (2025). PMID: 40727571 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  341. [341]

    Forgacs P, Wengenack NL, Hall L et al.. “Tuberculosis and trimethoprim-sulfamethoxazole.” Antimicrobial agents and chemotherapy (2009). PMID: 19564358 ↗

    L4OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  342. [342]

    Liang L, Quigley J, Theriault M et al.. “A chlorinated diketopiperazine antibiotic targets Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2025). PMID: 40741954 ↗

    L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  343. [343]

    Minato Y, Thiede JM, Kordus SL et al.. “Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.” Antimicrobial agents and chemotherapy (2015). PMID: 26033719 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  344. [344]

    Li D, Li L, Zhang Y et al.. “Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2025). PMID: 40261049 ↗

    L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  345. [345]

    Lin WH, Lee WT, Tsai HY et al.. “Disputed rpoB Mutations in Mycobacterium tuberculosis and Tuberculosis Treatment Outcomes.” Antimicrobial agents and chemotherapy (2021). PMID: 33846134 ↗

    L3OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  346. [346]

    Zhang M, Allen R, Ames L et al.. “Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2025). PMID: 40827962 ↗

    L5OTHERCited in: Diagnosis and Workup
  347. [347]

    Poonawala H, Zhang Y, Kuchibhotla S et al.. “Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2024). PMID: 38587412 ↗

    L5OTHERCited in: Diagnosis and Workup
  348. [348]

    Deshpande D, Srivastava S, Bendet P et al.. “Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.” Antimicrobial agents and chemotherapy (2018). PMID: 29180526 ↗

    L5OTHERCited in: Diagnosis and Workup, Special Hosts and Populations
  349. [349]

    Korycka-Machała M, Viljoen A, Pawełczyk J et al.. “1H-Benzo[d]Imidazole Derivatives Affect MmpL3 in Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2019). PMID: 31332069 ↗

    L5OTHERCited in: Diagnosis and Workup
  350. [350]

    Werngren J, Mansjö M, Glader M et al.. “Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2021). PMID: 34181476 ↗

    L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  351. [351]

    Park J, Choi S, Jeon YR et al.. “Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistant Mycobacterium avium complex infection.” Antimicrobial agents and chemotherapy (2025). PMID: 41416824 ↗

    L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  352. [352]

    Crabol Y, Catherinot E, Veziris N et al.. “Rifabutin: where do we stand in 2016?” The Journal of antimicrobial chemotherapy (2016). PMID: 27009031 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  353. [353]

    Rudilla H, Pérez-Guillén I, Rabanal F et al.. “Novel synthetic polymyxins kill Gram-positive bacteria.” The Journal of antimicrobial chemotherapy (2018). PMID: 30215733 ↗

    L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Special Hosts and Populations
  354. [354]

    Ghimire S, Van't Boveneind-Vrubleuskaya N, Akkerman OW et al.. “Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.” The Journal of antimicrobial chemotherapy (2016). PMID: 27231277 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  355. [355]

    Dookie N, Rambaran S, Padayatchi N et al.. “Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.” The Journal of antimicrobial chemotherapy (2018). PMID: 29360989 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, History and Evolution of Treatment
  356. [356]

    Yunivita V, Gafar F, Santoso P et al.. “Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.” The Journal of antimicrobial chemotherapy (2024). PMID: 38459759 ↗

    L2OTHERCited in: Diagnosis and Workup
  357. [357]

    Ballena-Caicedo J, Valladolid-Sandoval LAM, Zuzunaga-Montoya FE et al.. “Evolution of evidence on vitamin D supplementation in tuberculosis: A comprehensive umbrella review of nine systematic reviews.” Journal of clinical tuberculosis and other mycobacterial diseases (2026). PMID: 42389475 ↗

    L1SR_OBSCited in: Diagnosis and Workup, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  358. [358]

    Gan SH, KhinMar KW, Ang LW et al.. “Recurrent Tuberculosis Disease in Singapore.” Open forum infectious diseases (2021). PMID: 34307732 ↗

    L3OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control
  359. [359]

    Walsh KF, Lee MH, Chaguza C et al.. “Molecular Epidemiology of Isoniazid-resistant M tuberculosis in Port-au-Prince, Haiti.” Open forum infectious diseases (2024). PMID: 39119477 ↗

    L4OTHERCited in: Diagnosis and Workup
  360. [360]

    Moga S, Getahun M, Mohammed Z et al.. “The Ethiopian Third National Tuberculosis Drug Resistance Survey Incorporating Whole Genome Sequencing.” Open forum infectious diseases (2025). PMID: 40693102 ↗

    L4OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  361. [361]

    Walsh KF, Vilbrun SC, Souroutzidis A et al.. “Time to Culture Conversion of Bedaquiline and High-Dose Isoniazid for Drug-Resistant Tuberculosis.” Open forum infectious diseases (2022). PMID: 36172057 ↗

    L2OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  362. [362]

    Mambie A, Wallet F, Scherman L et al.. “Neither Neoplasia Nor Tuberculosis, but Francisella.” Open forum infectious diseases (2016). PMID: 27419157 ↗

    L4OTHERCited in: Diagnosis and Workup, Prognosis and Natural History
  363. [363]

    Ness T, Maphalala N, Khumalo W et al.. “Rapid Diagnostic Sequencing of Stool DNA Using Targeted Nanopore Sequencing in Patients With a Pulmonary Tuberculosis Diagnosis.” Open forum infectious diseases (2025). PMID: 40212033 ↗

    L4OTHERCited in: Diagnosis and Workup
  364. [364]

    Mase A, Lowenthal P, True L et al.. “Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis.” Open forum infectious diseases (2022). PMID: 36601556 ↗

    L2OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  365. [365]

    Weber SF, Wolf P, Wetzstein N et al.. “Diagnostic Accuracy of Lung and Abdominal Ultrasound for Tuberculosis in a German Multicenter Cohort of Patients With Presumed Tuberculosis Disease.” Open forum infectious diseases (2024). PMID: 39691283 ↗

    L2OTHERCited in: Diagnosis and Workup
  366. [366]

    Fischer H, Qian L, Li Z et al.. “Prior Screening for Latent Tuberculosis Among Patients Diagnosed With Tuberculosis Disease: Missed Opportunities?” Open forum infectious diseases (2023). PMID: 38023560 ↗

    L2OTHERCited in: Diagnosis and Workup
  367. [367]

    Dugdale CM, Zachary KC, McEvoy DS et al.. “Second Time's the Charm? Assessing the Sensitivity and Yield of Inpatient Diagnostic Algorithms for Pulmonary Tuberculosis in a Low-Prevalence Setting.” Open forum infectious diseases (2024). PMID: 38872849 ↗

    L4OTHERCited in: Diagnosis and Workup
  368. [368]

    Acosta F, Chernyaeva E, Mendoza L et al.. “Mycobacterium bovis in Panama, 2013.” Emerging infectious diseases (2015). PMID: 25988479 ↗

    L4OTHERCited in: Diagnosis and Workup, History and Evolution of Treatment
  369. [369]

    Skiba Y, Mokrousov I, Nabirova D et al.. “Mycobacterium tuberculosis RD-Rio Strain in Kazakhstan.” Emerging infectious diseases (2019). PMID: 30789328 ↗

    L4OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  370. [370]

    Kuge T, Fukushima K, Matsumoto Y et al.. “Chronic Pulmonary Disease Caused by Tsukamurella toyonakaense.” Emerging infectious diseases (2022). PMID: 35731181 ↗

    L4OTHERCited in: Diagnosis and Workup
  371. [371]

    Günther G, van Leth F, Alexandru S et al.. “Multidrug-resistant tuberculosis in Europe, 2010-2011.” Emerging infectious diseases (2015). PMID: 25693485 ↗

    L3OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  372. [372]

    Wang H, Cheng D, Qian X et al.. “A diagnostic performance study of multiplex polymerase chain reaction-based targeted next-generation sequencing for the accurate identification of Mycobacterium tuberculosis in bronchoalveolar lavage fluid.” Frontiers in cellular and infection microbiology (2026). PMID: 42434424 ↗

    L2OTHERCited in: Diagnosis and Workup
  373. [373]

    Zhan S, Zheng Y, Wu T et al.. “Nucleosome-targeted host DNA depletion enables automated plasma metagenomic sequencing for sensitive detection of bloodstream pathogens.” Journal of translational medicine (2026). PMID: 42426749 ↗

    L5OTHERCited in: Diagnosis and Workup
  374. [374]

    Nakiboneka R, Margaritella N, Nyirenda TS et al.. “Comparative assessment of Host transcriptomic- and bacteriological- markers for monitoring treatment response among active tuberculosis patients: a longitudinal study.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42419448 ↗

    L2OTHERCited in: Diagnosis and Workup
  375. [375]

    Chen Y-L, Guan C-P, Deng Y-F et al.. “Phenotypic discordance in rifampicin resistance detection among Mycobacterium tuberculosis isolates from China: insights from whole-genome sequencing and a structured literature review.” Microbiology spectrum (2026). PMID: 42405793 ↗

    L4REVIEW_NARRATIVECited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  376. [376]

    Paciello LG, Jara L, Salina M et al.. “Screening for tuberculosis in prisons: efficacy of a breath-based diagnostic approach in a high prevalence setting.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42398697 ↗

    L4OTHERCited in: Diagnosis and Workup
  377. [377]

    Zhou J, Lin X, Zhang Y et al.. “Evaluation of nucleic acid-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for rapid identification of Mycobacterium tuberculosis and drug resistance in patients with retreatment tuberculosis.” Frontiers in microbiology (2026). PMID: 42395904 ↗

    L4OTHERCited in: Diagnosis and Workup
  378. [378]

    Shu W, Cai Q, Huang Y et al.. “Rare emergence of delamanid resistance in multidrug-/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in China.” Annals of clinical microbiology and antimicrobials (2026). PMID: 42393731 ↗

    L2OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  379. [379]

    Gupta A, Nayak U, Ram M et al.. “Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17578786 ↗

    L2RCTCited in: Severity Assessment and Risk Stratification
  380. [380]

    Miyahara S, Ramchandani R, Kim S et al.. “Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31414121 ↗

    L5TRIAL_NONRANDOMCited in: Severity Assessment and Risk Stratification
  381. [381]

    O'Shea MK, Koh GC, Munang M et al.. “Time-to-detection in culture predicts risk of Mycobacterium tuberculosis transmission: a cohort study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24729491 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  382. [382]

    Baker MA, Lin HH, Chang HY et al.. “The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2012). PMID: 22238171 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  383. [383]

    Muñoz L, Casas S, Juanola X et al.. “Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 25313252 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  384. [384]

    Turkova A, Wills GH, Wobudeya E et al.. “Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.” The New England journal of medicine (2022). PMID: 35263517 ↗

    L1RCTCited in: Severity Assessment and Risk Stratification, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Hosts and Populations
  385. [385]

    Chiang SS, Khan FA, Milstein MB et al.. “Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2014). PMID: 25108337 ↗

    L1SR_OBSCited in: Severity Assessment and Risk Stratification
  386. [386]

    Romanowski K, Baumann B, Basham CA et al.. “Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2019). PMID: 31324519 ↗

    L2SR_OBSCited in: Severity Assessment and Risk Stratification
  387. [387]

    Rubin DT, Allegretti JR, Panés J et al.. “Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.” Lancet (London, England) (2024). PMID: 39706209 ↗

    L1RCTCited in: Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications
  388. [388]

    Saunders MJ, Wingfield T, Tovar MA et al.. “A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study.” The Lancet. Infectious diseases (2017). PMID: 28827142 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  389. [389]

    Carroll MW, Jeon D, Mountz JM et al.. “Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis.” Antimicrobial agents and chemotherapy (2013). PMID: 23733467 ↗

    L1RCTCited in: Severity Assessment and Risk Stratification
  390. [390]

    Jenkins HE, Tolman AW, Yuen CM et al.. “Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates.” Lancet (London, England) (2014). PMID: 24671080 ↗

    L2SR_OBSCited in: Severity Assessment and Risk Stratification, Antimicrobial Resistance and Stewardship
  391. [391]

    Oberhelman RA, Soto-Castellares G, Gilman RH et al.. “Diagnostic approaches for paediatric tuberculosis by use of different specimen types, culture methods, and PCR: a prospective case-control study.” The Lancet. Infectious diseases (2010). PMID: 20656559 ↗

    L3CASE_CONTROLCited in: Severity Assessment and Risk Stratification
  392. [392]

    Huang C, Huang L, Wang Y et al.. “6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.” Lancet (London, England) (2021). PMID: 33428867 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification, Complications
  393. [393]

    Parida SK, Poiret T, Zhenjiang L et al.. “T-Cell Therapy: Options for Infectious Diseases.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26409284 ↗

    L5REVIEW_NARRATIVECited in: Severity Assessment and Risk Stratification, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  394. [394]

    Peetluk LS, Rebeiro PF, Ridolfi FM et al.. “A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34214166 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  395. [395]

    Grint DJ, Dhillon J, Butcher PD et al.. “Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40991667 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  396. [396]

    Thao LTP, Heemskerk AD, Geskus RB et al.. “Prognostic Models for 9-Month Mortality in Tuberculous Meningitis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29029055 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  397. [397]

    Marais S, Meintjes G, Pepper DJ et al.. “Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2012). PMID: 23097584 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  398. [398]

    . “Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study.” Lancet (London, England) (2019). PMID: 31257127 ↗

    L3CASE_CONTROLCited in: Severity Assessment and Risk Stratification
  399. [399]

    Balcells ME, Thomas SL, Godfrey-Faussett P et al.. “Isoniazid preventive therapy and risk for resistant tuberculosis.” Emerging infectious diseases (2006). PMID: 16704830 ↗

    L2SR_OBSCited in: Severity Assessment and Risk Stratification
  400. [400]

    Naidu G, Moore DP, Reljic T et al.. “Clinical practice guidelines for the management of fever and neutropenia in South African children and adolescents with cancer.” South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (2026). PMID: 42246864 ↗

    L1GUIDELINECited in: Severity Assessment and Risk Stratification
  401. [401]

    de Oliveira VF, Prats JAGG, Bollela VR et al.. “Clinical Features and Mortality of Chronic Pulmonary Aspergillosis in Brazil: a Multicenter Cohort Study.” Open forum infectious diseases (2026). PMID: 41536616 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  402. [402]

    Battegay M, Nüesch R, Hirschel B et al.. “Immunological recovery and antiretroviral therapy in HIV-1 infection.” The Lancet. Infectious diseases (2006). PMID: 16631548 ↗

    L5REVIEW_NARRATIVECited in: Severity Assessment and Risk Stratification, Prevention and Infection Control
  403. [403]

    Edelyne J, Wardoyo MP, Putri LZ et al.. “C-reactive protein as a predictor of mortality in tuberculosis: systematic review and meta-analysis.” BMC infectious diseases (2026). PMID: 42092814 ↗

    L2SR_OBSCited in: Severity Assessment and Risk Stratification
  404. [404]

    Chávez-Domínguez RL, Viettri M, Torres M et al.. “Type 2 diabetes mellitus associated microRNAs in tuberculosis susceptibility: a systematic review and bioinformatic analysis.” Frontiers in endocrinology (2026). PMID: 41809532 ↗

    L3SR_OBSCited in: Severity Assessment and Risk Stratification
  405. [405]

    Schwalbe N, Wahl B. “Artificial intelligence and the future of global health.” Lancet (London, England) (2020). PMID: 32416782 ↗

    L5REVIEW_NARRATIVECited in: Severity Assessment and Risk Stratification
  406. [406]

    Kwak SH, Choi H, Lee SW et al.. “Clinical outcomes and recurrence after treatment of asymptomatic pulmonary tuberculosis: A nationwide cohort study.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42155664 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  407. [407]

    Shi N, Wan Z, Wen L et al.. “Development and validation of a habitat-based computed tomography radiomics model for differentiating isolated lung cancer, isolated tuberculoma, and coexistence of tuberculosis with lung cancer: a dual-center retrospective study.” Translational lung cancer research (2026). PMID: 41982687 ↗

    L3COHORTCited in: Severity Assessment and Risk Stratification
  408. [408]

    Bibbins-Domingo K, Grossman DC, Curry SJ et al.. “Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement.” JAMA (2016). PMID: 27599331 ↗

    L1OTHERCited in: Severity Assessment and Risk Stratification
  409. [409]

    Sudarto S, Hafy Z, Saleh I et al.. “The Role of Toll-like Receptor 2 Polymorphisms in Susceptibility to and Severity of Tuberculosis: A Systematic Review.” Pathogens (Basel, Switzerland) (2026). PMID: 42075681 ↗

    L3SR_OBSCited in: Severity Assessment and Risk Stratification
  410. [410]

    Ma N, Pu L, Zang Z et al.. “Application of targeted next-generation sequencing in the etiological diagnosis of peritoneal dialysis-associated peritonitis: a single-center prospective cohort study.” International urology and nephrology (2026). PMID: 42348136 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  411. [411]

    Zini T, Tsuro U, Faye LM et al.. “Predictors of Treatment Outcomes Among HIV-Positive Patients with Drug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: A Retrospective Cohort Study.” International journal of environmental research and public health (2026). PMID: 42074413 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  412. [412]

    Wu L, Tang T, Huang X et al.. “Clinical classification of chronic obstructive pulmonary disease with invasive pulmonary aspergillosis: a retrospective study.” Journal of thoracic disease (2026). PMID: 41816391 ↗

    L4COHORTCited in: Severity Assessment and Risk Stratification
  413. [413]

    Gou L, Gao F, Tiheiran M et al.. “Evaluation of the Clinical, Laboratory, and Radiological Findings and Treatment of 19 Cases of Pancreatic Echinococcosis.” Open forum infectious diseases (2020). PMID: 32405510 ↗

    L4OTHERCited in: Severity Assessment and Risk Stratification, History and Evolution of Treatment
  414. [414]

    Tai AYC, Athan E, Friedman ND et al.. “Increased Severity and Spread of Mycobacterium ulcerans, Southeastern Australia.” Emerging infectious diseases (2018). PMID: 28980523 ↗

    L4OTHERCited in: Severity Assessment and Risk Stratification
  415. [415]

    Pavlin BI, Schloegel LM, Daszak P. “Risk of importing zoonotic diseases through wildlife trade, United States.” Emerging infectious diseases (2009). PMID: 19891857 ↗

    L5OTHERCited in: Severity Assessment and Risk Stratification
  416. [416]

    Reznik M, Ozuah PO. “Tuberculin skin testing in children.” Emerging infectious diseases (2006). PMID: 16704827 ↗

    L5OTHERCited in: Severity Assessment and Risk Stratification
  417. [417]

    Padmapriyadarsini C, Oswal VS, Jain CD et al.. “Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39194339 ↗

    L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  418. [418]

    Thompson MA, Aberg JA, Hoy JF et al.. “Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.” JAMA (2012). PMID: 22820792 ↗

    L1GUIDELINECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Special Hosts and Populations
  419. [419]

    Nguyen QD, Merrill PT, Jaffe GJ et al.. “Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.” Lancet (London, England) (2016). PMID: 27542302 ↗

    L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications
  420. [420]

    Reddy M, Gill SS, Kalkar SR et al.. “Oral drug therapy for multiple neglected tropical diseases: a systematic review.” JAMA (2007). PMID: 17954542 ↗

    L5SR_OBSCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  421. [421]

    Ernest JP, Sarathy J, Wang N et al.. “Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis.” Antimicrobial agents and chemotherapy (2021). PMID: 34252307 ↗

    L4SR_OBSCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  422. [422]

    Metarfi Y, Chellal W, Ben Khadda Z et al.. “Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review.” The Journal of antimicrobial chemotherapy (2025). PMID: 40256853 ↗

    L2SR_OBSCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Special Hosts and Populations
  423. [423]

    Dey T, Brigden G, Cox H et al.. “Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.” The Journal of antimicrobial chemotherapy (2012). PMID: 23054996 ↗

    L2SR_OBSCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  424. [424]

    . “Beijing/W genotype Mycobacterium tuberculosis and drug resistance.” Emerging infectious diseases (2006). PMID: 16704829 ↗

    L3SR_OBSCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  425. [425]

    Sterling TR, Pham PA, Chaisson RE. “HIV infection-related tuberculosis: clinical manifestations and treatment.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20397952 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
  426. [426]

    Llamas-Lopez A, Seddon JA, Chow FC et al.. “Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysis.” Open forum infectious diseases (2025). PMID: 41064692 ↗

    L1TRIAL_NONRANDOMCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History
  427. [427]

    Ge S, Liu K, Jiang X et al.. “Prevalence, Progression, and Treatment of Asymptomatic Tuberculosis: A Prospective Cohort Study in Lanxi County, Zhejiang Province, China.” Open forum infectious diseases (2025). PMID: 40416508 ↗

    L2COHORTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  428. [428]

    Sati H, Carrara E, Savoldi A et al.. “The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance.” The Lancet. Infectious diseases (2025). PMID: 40245910 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  429. [429]

    Tacconelli E, Carrara E, Savoldi A et al.. “Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.” The Lancet. Infectious diseases (2017). PMID: 29276051 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  430. [430]

    Wasserman S, Donovan J, Kestelyn E et al.. “Advancing the chemotherapy of tuberculous meningitis: a consensus view.” The Lancet. Infectious diseases (2024). PMID: 39342951 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  431. [431]

    Dartois V, Dick T. “Toward better cures for Mycobacterium abscessus lung disease.” Clinical microbiology reviews (2024). PMID: 39360834 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  432. [432]

    Shamebo T, Zewude A, Mohammed T et al.. “Molecular Epidemiology of Mycobacterium tuberculosis in the Middle East and North Africa: A Systematic Review and Meta-Analysis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42419447 ↗

    L2SR_OBSCited in: Empiric Management, Acute Care and Source Control
  433. [433]

    Huang K, Yang T, Xu J et al.. “Prevalence, risk factors, and management of asthma in China: a national cross-sectional study.” Lancet (London, England) (2019). PMID: 31230828 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations
  434. [434]

    Maartens G, Wilkinson RJ. “Tuberculosis.” Lancet (London, England) (2007). PMID: 17719083 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  435. [435]

    Csete J, Kamarulzaman A, Kazatchkine M et al.. “Public health and international drug policy.” Lancet (London, England) (2016). PMID: 27021149 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  436. [436]

    Jamison DT, Summers LH, Chang AY et al.. “Global health 2050: the path to halving premature death by mid-century.” Lancet (London, England) (2024). PMID: 39419055 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  437. [437]

    Sarifah LM, Madolangan J, Ardiansyah A et al.. “Treatment outcomes and adverse events associated with intermittent versus daily continuation-phase regimens in drug-susceptible tuberculosis patients in Makassar, Indonesia: an observational cohort study.” BMC infectious diseases (2026). PMID: 42401852 ↗

    L2COHORTCited in: Empiric Management, Acute Care and Source Control, Complications, Special Hosts and Populations
  438. [438]

    Shah NS, Pratt R, Armstrong L et al.. “Extensively drug-resistant tuberculosis in the United States, 1993-2007.” JAMA (2008). PMID: 19001626 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Special Hosts and Populations
  439. [439]

    Meikle V, Zhang L, Niederweis M. “Intricate link between siderophore secretion and drug efflux in Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2023). PMID: 37676015 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  440. [440]

    Ramey ME, Kaya F, Bauman AA et al.. “Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.” Antimicrobial agents and chemotherapy (2023). PMID: 37791784 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  441. [441]

    Lyons MA. “Pharmacodynamics and Bactericidal Activity of Bedaquiline in Pulmonary Tuberculosis.” Antimicrobial agents and chemotherapy (2021). PMID: 34871099 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control
  442. [442]

    Reichlen MJ, Born SEM, Lyons MA et al.. “Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency.” Antimicrobial agents and chemotherapy (2023). PMID: 36622159 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  443. [443]

    Sao Emani C, Williams MJ, Wiid IJ et al.. “Compounds with Potential Activity against Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2018). PMID: 29437626 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  444. [444]

    Koele SE, van Beek SW, Maartens G et al.. “Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment.” Antimicrobial agents and chemotherapy (2022). PMID: 35007141 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  445. [445]

    Goh M, Eisenkraft Klein D, Kesselheim AS. “The curious constraints on clofazimine.” The Journal of antimicrobial chemotherapy (2026). PMID: 41259059 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  446. [446]

    Mudde SE, Upton AM, Lenaerts A et al.. “Delamanid or pretomanid? A Solomonic judgement!” The Journal of antimicrobial chemotherapy (2022). PMID: 35089314 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  447. [447]

    van Heeswijk RP, Dannemann B, Hoetelmans RM. “Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.” The Journal of antimicrobial chemotherapy (2014). PMID: 24860154 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  448. [448]

    Cholo MC, Steel HC, Fourie PB et al.. “Clofazimine: current status and future prospects.” The Journal of antimicrobial chemotherapy (2011). PMID: 22020137 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  449. [449]

    Abedinzadeh M, Gaeini M, Sardari S. “Natural antimicrobial peptides against Mycobacterium tuberculosis.” The Journal of antimicrobial chemotherapy (2015). PMID: 25681127 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  450. [450]

    Sousa M, Pozniak A, Boffito M. “Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs.” The Journal of antimicrobial chemotherapy (2008). PMID: 18713760 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  451. [451]

    Kumar A, Boradia VM, Thakare R et al.. “Repurposing ethyl bromopyruvate as a broad-spectrum antibacterial.” The Journal of antimicrobial chemotherapy (2019). PMID: 30689890 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  452. [452]

    Cholo MC, Mothiba MT, Fourie B et al.. “Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.” The Journal of antimicrobial chemotherapy (2016). PMID: 27798208 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History
  453. [453]

    Almeida Da Silva PE, Palomino JC. “Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.” The Journal of antimicrobial chemotherapy (2011). PMID: 21558086 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  454. [454]

    Samal J, Behera MR, Dehury RK et al.. “Prevalence and Predictors of Anxiety among Tuberculosis Patients in India: A Systematic Review and Meta-Analysis.” Journal of epidemiology and global health (2026). PMID: 42426337 ↗

    L4SR_OBSCited in: Empiric Management, Acute Care and Source Control
  455. [455]

    Anand PK, Patel D, Dewasi G et al.. “Challenges and Barriers in Implementation of National Tuberculosis Elimination Program Guidelines at Nutrition Rehabilitation Centers in India: A Systematic Review.” Journal of epidemiology and global health (2026). PMID: 42418058 ↗

    L4SR_OBSCited in: Empiric Management, Acute Care and Source Control
  456. [456]

    Acharya P, Bhattarai N, Kunwar BR et al.. “Risk factors of multi-drug-resistant tuberculosis among tuberculosis patients in Bagmati Province, Nepal: a matched case-control study.” BMC infectious diseases (2026). PMID: 42426652 ↗

    L3CASE_CONTROLCited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  457. [457]

    Richardson S, Vorster P, Burger R et al.. “Conversational mHealth Platform Designed to Support Tuberculosis Treatment Adherence in Low-Income South African Patients: Pilot Cohort Study.” JMIR formative research (2026). PMID: 42421424 ↗

    L2COHORTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  458. [458]

    Tzelios C, Neuhausser WM, Ryley D et al.. “Female Genital Tuberculosis.” Open forum infectious diseases (2022). PMID: 36447614 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Special Hosts and Populations
  459. [459]

    Lee EH, Yong SH, Leem AY et al.. “Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes.” Open forum infectious diseases (2019). PMID: 30949546 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  460. [460]

    Malenfant JH, Brewer TF. “Rifampicin Mono-Resistant Tuberculosis-A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control.” Open forum infectious diseases (2021). PMID: 33623803 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  461. [461]

    Barreto-Duarte B, Villalva-Serra K, Miguez-Pinto JP et al.. “Retreatment and Anti-tuberculosis Therapy Outcomes in Brazil Between 2015 and 2022: A Nationwide Study.” Open forum infectious diseases (2024). PMID: 39100532 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History, Special Hosts and Populations
  462. [462]

    Mave V, Gaikwad S, Barthwal M et al.. “Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, India.” Open forum infectious diseases (2021). PMID: 33884278 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History
  463. [463]

    Quispe-Juli CU, Gallardo-Cartagena JA, Otero L et al.. “Challenges and Opportunities for Improved Tuberculosis and HIV Prevention in South America.” Open forum infectious diseases (2026). PMID: 41918956 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Special Hosts and Populations
  464. [464]

    Louie JK, Agraz-Lara R, Velásquez GE et al.. “Experience With Four-Month Rifapentine and Moxifloxacin-Based Tuberculosis Treatment in San Francisco.” Open forum infectious diseases (2024). PMID: 38634108 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control, Complications
  465. [465]

    Araújo-Pereira M, Arriaga MB, Carvalho ACC et al.. “Isoniazid Monoresistance and Antituberculosis Treatment Outcome in Persons With Pulmonary Tuberculosis in Brazil.” Open forum infectious diseases (2024). PMID: 38221983 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control
  466. [466]

    MacPherson DW, Gushulak BD, Baine WB et al.. “Population mobility, globalization, and antimicrobial drug resistance.” Emerging infectious diseases (2009). PMID: 19891858 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship, Complications
  467. [467]

    Lahiri R, Adams LB, Thomas SS et al.. “Sensitivity of Mycobacterium leprae to Telacebec.” Emerging infectious diseases (2022). PMID: 35202539 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  468. [468]

    Novosad SA, Beekmann SE, Polgreen PM et al.. “Treatment of Mycobacterium abscessus Infection.” Emerging infectious diseases (2016). PMID: 26890211 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  469. [469]

    Sindani I, Fitzpatrick C, Falzon D et al.. “Multidrug-resistant tuberculosis, Somalia, 2010-2011.” Emerging infectious diseases (2013). PMID: 23621911 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  470. [470]

    Kherabi Y, Fréchet-Jachym M, Rioux C et al.. “Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.” Emerging infectious diseases (2022). PMID: 35997386 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications
  471. [471]

    Sarr A, Alves D, Cissé-Diallo VM et al.. “Burden of infectious diseases in a West African tertiary hospital: a two-year retrospective study at CHNU de Fann, Senegal.” Journal of infection in developing countries (2026). PMID: 42430538 ↗

    L4COHORTCited in: Empiric Management, Acute Care and Source Control
  472. [472]

    Wang X, Xu H. “Anti-tuberculosis drug treatment and adverse reactions in 546 children with tuberculosis in Chongqing, China: A 10-year retrospective study.” The Journal of international medical research (2026). PMID: 42421524 ↗

    L4COHORTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  473. [473]

    Mkono L, Sineke N, Dlatu N et al.. “Epidemiology and treatment outcomes of TB-HIV co-infection in a rural South African setting: an exploratory analysis of retreatment and contextual factors.” Frontiers in public health (2026). PMID: 42433412 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control
  474. [474]

    Li Y, Gao H, Li X et al.. “Epidemiological Characteristics and Spatiotemporal Cluster Analysis of Multidrug-Resistant and Rifampicin-Resistant Tuberculosis Among Older People - China, 2019-2025.” China CDC weekly (2026). PMID: 42433222 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control
  475. [475]

    Yan G, Dong W, Fan J et al.. “MRI-defined compression stages and postoperative neurological recovery in thoracic spinal tuberculosis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42431540 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control
  476. [476]

    Calderin JM, Wasserman S, Antilus-Sainte R et al.. “Central nervous system antituberculosis drug exposures in a rabbit model of tuberculous meningitis.” Antimicrobial agents and chemotherapy (2026). PMID: 42429967 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  477. [477]

    Bruning-Barry R, Ambroso JL, Yang X et al.. “Safety evaluation of pretomanid, an anti-tuberculosis drug, for the treatment of pregnant and lactating women.” Antimicrobial agents and chemotherapy (2026). PMID: 42429813 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  478. [478]

    Huang R, He Y, Yang J et al.. “Synergism in drug combination of new tuberculosis antibiotics for drug-resistant Mycobacterium tuberculosis in vitro.” Microbiology spectrum (2026). PMID: 42429417 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  479. [479]

    Paton NI, Cousins C, Suresh C et al.. “Treatment Strategy for Rifampin-Susceptible Tuberculosis.” The New England journal of medicine (2023). PMID: 36808186 ↗

    L1RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  480. [480]

    Wei X, Hicks JP, Zhang Z et al.. “Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial.” Lancet (London, England) (2024). PMID: 38309280 ↗

    L1RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History
  481. [481]

    Jacobs TG, Svensson EM, Musiime V et al.. “Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.” The Journal of antimicrobial chemotherapy (2020). PMID: 32785712 ↗

    L2SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Special Hosts and Populations
  482. [482]

    van der Feltz I, Wen H, Aarnoutse RE et al.. “Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology.” The Journal of antimicrobial chemotherapy (2025). PMID: 40808635 ↗

    L5SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  483. [483]

    Abdelwahab MT, Wasserman S, Brust JCM et al.. “Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis.” Antimicrobial agents and chemotherapy (2021). PMID: 34543098 ↗

    L2RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  484. [484]

    Wang Q, Pang Y, Jing W et al.. “Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China.” Antimicrobial agents and chemotherapy (2018). PMID: 29378718 ↗

    L1RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  485. [485]

    Liu W, Xu N, Li W et al.. “Pharmacokinetics and safety of rifapentine in children: dosing for latent tuberculosis infection.” The Journal of antimicrobial chemotherapy (2025). PMID: 39945044 ↗

    L4TRIAL_NONRANDOMCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
  486. [486]

    Maranchick NF, Peloquin CA, Haley CA. “Linezolid Dosing and Pharmacokinetics in North American Patients With Tuberculosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39834217 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  487. [487]

    Purohit D, van Wijk R, Kafeero P et al.. “Impact of High-Dose Rifampicin on Linezolid Pharmacokinetics in Tuberculous Meningitis.” Open forum infectious diseases (2026). PMID: 41969755 ↗

    L2TRIAL_NONRANDOMCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  488. [488]

    Caño-Muñiz S, Anthony R, Niemann S et al.. “New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State.” Clinical microbiology reviews (2017). PMID: 29187395 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  489. [489]

    Lindsey JA, Easton AV, Modestil H et al.. “Rifampin Mono-Resistant Tuberculosis in New York City, 2010-2021: A Retrospective Case Series.” Open forum infectious diseases (2023). PMID: 38023554 ↗

    L4CASE_REPORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  490. [490]

    Boulle A, Van Cutsem G, Cohen K et al.. “Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.” JAMA (2008). PMID: 18677025 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  491. [491]

    Havlir DV, Getahun H, Sanne I et al.. “Opportunities and challenges for HIV care in overlapping HIV and TB epidemics.” JAMA (2008). PMID: 18647985 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  492. [492]

    Singh S, Gumbo T, Boorgula GD et al.. “Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model.” Antimicrobial agents and chemotherapy (2023). PMID: 38131673 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  493. [493]

    Alghamdi WA, Alsultan A, Al-Shaer MH et al.. “Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.” Antimicrobial agents and chemotherapy (2019). PMID: 30858211 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  494. [494]

    Alsultan A, Savic R, Dooley KE et al.. “Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.” Antimicrobial agents and chemotherapy (2017). PMID: 28289033 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  495. [495]

    Olivença F, Pires D, Silveiro C et al.. “Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis.” Antimicrobial agents and chemotherapy (2024). PMID: 38411952 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  496. [496]

    Othman NA, Mohd Amin MCI, Yow HY et al.. “Lipid-based nanocarriers as transformative treatment in tuberculosis: a systematic review of therapeutic efficacy.” Nanomedicine (London, England) (2026). PMID: 42366743 ↗

    L5SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  497. [497]

    Kloprogge F, Mwandumba HC, Banda G et al.. “Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis.” Open forum infectious diseases (2020). PMID: 32733976 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  498. [498]

    Tsang CA, Patel NN, Stout JE et al.. “Factors Associated With Receiving Longer Than Recommended Therapy Among Culture-Negative Pulmonary Tuberculosis Patients.” Open forum infectious diseases (2022). PMID: 36519121 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  499. [499]

    Pamela BE, Vasudevan P, Thamizhmaran S et al.. “Monocyte Gene Expression Distinguishes Enhancing Brain Parenchymal Cysticercal Granulomas From Tuberculomas.” Open forum infectious diseases (2021). PMID: 34557561 ↗

    L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  500. [500]

    Magodoro IM, Aluoch A, Claggett B et al.. “Association Between Mycobacterium tuberculosis Sensitization and Insulin Resistance Among US Adults Screened for Type 2 Diabetes Mellitus.” Open forum infectious diseases (2024). PMID: 39469603 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  501. [501]

    Yun HY, Chang V, Radtke KK et al.. “Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis.” Open forum infectious diseases (2021). PMID: 35146045 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  502. [502]

    Yang J, Ko JH, Cho SY et al.. “Clinical Outcome of Rifabutin-based Treatment for Pulmonary Tuberculosis in Solid Organ Transplant Recipients.” Open forum infectious diseases (2025). PMID: 41064696 ↗

    L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  503. [503]

    Dahl VN, Butova T, Rosenthal A et al.. “Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017-2022.” Emerging infectious diseases (2024). PMID: 38526186 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  504. [504]

    Laycock KM, Karmazyn B, Prabhudas-Strycker K et al.. “Disseminated Tuberculosis With Cavitary Lung Disease in a Very Preterm Infant.” Pediatrics (2026). PMID: 42331354 ↗

    L4CASE_REPORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  505. [505]

    Arslan S, Sert A, Özçelik M et al.. “Disseminated Tuberculosis and Early-Onset SLE in a Child with a Novel STAT1 Gain-of-Function Mutation: a Case Report.” Journal of clinical immunology (2026). PMID: 42319627 ↗

    L4CASE_REPORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  506. [506]

    Daghfal J, Al Balushi S, Chaponda M et al.. “Epidemiology of Tuberculosis in Qatar: Eight-year Retrospective Cohort Study.” International journal of mycobacteriology (2026). PMID: 42378608 ↗

    L2COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  507. [507]

    Luo M, Zhou G, Fan Y et al.. “Comparative in vitro antimicrobial susceptibility profiles of clofazimine and pyrifazimine against clinical isolates of Mycobacterium tuberculosis in southwest China.” Microbiology spectrum (2026). PMID: 42405759 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  508. [508]

    Pilote É, Sheehan NL, Marsot A. “Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.” Clinical pharmacokinetics (2026). PMID: 42377866 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  509. [509]

    Qian J, Sun J, Liu Y et al.. “The role of long non-coding RNA HCP5 in ulcerative cutaneous tuberculosis therapy introduction.” Frontiers in cellular and infection microbiology (2026). PMID: 42369184 ↗

    L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  510. [510]

    Eggeling J, Sester M, Lange C et al.. “PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapy.” Frontiers in immunology (2026). PMID: 42367813 ↗

    L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  511. [511]

    Peloquin CA, Berning SE, Nitta AT et al.. “Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2004). PMID: 15156439 ↗

    L1RCTCited in: History and Evolution of Treatment
  512. [512]

    Purchase SE, Brigden J, Seddon JA et al.. “Risk of Tuberculosis Infection in Young Children Exposed to Multidrug-resistant Tuberculosis in the TB-CHAMP Multi-site Randomized Controlled Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40440402 ↗

    L1RCTCited in: History and Evolution of Treatment
  513. [513]

    Podell BK, Aibana O, Huang CC et al.. “The Impact of Vitamin A Deficiency on Tuberculosis Progression.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35486953 ↗

    L3RCTCited in: History and Evolution of Treatment, Complications
  514. [514]

    . “From the Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis.” JAMA (1993). PMID: 8336361 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  515. [515]

    Muñoz P, Palomo J, Muñoz R et al.. “Tuberculosis in heart transplant recipients.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (1995). PMID: 8562750 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  516. [516]

    Aldridge RW, Story A, Hwang SW et al.. “Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis.” Lancet (London, England) (2017). PMID: 29137869 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  517. [517]

    Campbell JR, Falzon D, Mirzayev F et al.. “Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis.” Emerging infectious diseases (2020). PMID: 31922953 ↗

    L5GUIDELINECited in: History and Evolution of Treatment
  518. [518]

    Bekker LG, Wood R. “The changing natural history of tuberculosis and HIV coinfection in an urban area of hyperendemicity.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20397950 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prognosis and Natural History
  519. [519]

    Suárez I, Maria Fünger S, Jung N et al.. “Severe disseminated tuberculosis in HIV-negative refugees.” The Lancet. Infectious diseases (2019). PMID: 31182290 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  520. [520]

    Kempker RR, Vashakidze S, Solomonia N et al.. “Surgical treatment of drug-resistant tuberculosis.” The Lancet. Infectious diseases (2012). PMID: 22281142 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  521. [521]

    Kengo A, Nabisere R, Gausi K et al.. “Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.” Antimicrobial agents and chemotherapy (2023). PMID: 37850738 ↗

    L2RCTCited in: History and Evolution of Treatment, Special Hosts and Populations
  522. [522]

    Kim JS, Kim YH, Lee SH et al.. “Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.” Antimicrobial agents and chemotherapy (2021). PMID: 34871098 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications
  523. [523]

    Lombardi A, Pappas F, Nedelman J et al.. “Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjects.” Antimicrobial agents and chemotherapy (2024). PMID: 39194204 ↗

    L4RCTCited in: History and Evolution of Treatment
  524. [524]

    Pham MM, Podany AT, Mwelase N et al.. “Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.” Antimicrobial agents and chemotherapy (2022). PMID: 35943252 ↗

    L2RCTCited in: History and Evolution of Treatment
  525. [525]

    Ignatius EH, Abdelwahab MT, Hendricks B et al.. “Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis.” Antimicrobial agents and chemotherapy (2021). PMID: 33229425 ↗

    L1RCTCited in: History and Evolution of Treatment
  526. [526]

    Gurumurthy M, Verma R, Naftalin CM et al.. “Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.” The Journal of antimicrobial chemotherapy (2017). PMID: 28333342 ↗

    L1RCTCited in: History and Evolution of Treatment
  527. [527]

    Gumbo T, Chigutsa E, Pasipanodya J et al.. “The pyrazinamide susceptibility breakpoint above which combination therapy fails.” The Journal of antimicrobial chemotherapy (2014). PMID: 24821594 ↗

    L2RCTCited in: History and Evolution of Treatment
  528. [528]

    Weiner M, Gelfond J, Johnson-Pais TL et al.. “Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis.” The Journal of antimicrobial chemotherapy (2021). PMID: 33374006 ↗

    L2RCTCited in: History and Evolution of Treatment
  529. [529]

    Heinrich N, Dawson R, du Bois J et al.. “Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.” The Journal of antimicrobial chemotherapy (2015). PMID: 25630641 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications
  530. [530]

    Lamorde M, Byakika-Kibwika P, Okaba-Kayom V et al.. “Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.” The Journal of antimicrobial chemotherapy (2010). PMID: 21047828 ↗

    L1RCTCited in: History and Evolution of Treatment
  531. [531]

    Zhang J, Zhu L, Stonier M et al.. “Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.” The Journal of antimicrobial chemotherapy (2011). PMID: 21712242 ↗

    L1RCTCited in: History and Evolution of Treatment
  532. [532]

    Smithuis FM, White NJ. “Spend wisely to eliminate malaria.” The Lancet. Infectious diseases (2021). PMID: 34953537 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  533. [533]

    Behr MA. “BCG--different strains, different vaccines?” The Lancet. Infectious diseases (2002). PMID: 11901655 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  534. [534]

    Khan PY, Yates TA, Osman M et al.. “Transmission of drug-resistant tuberculosis in HIV-endemic settings.” The Lancet. Infectious diseases (2018). PMID: 30554996 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Special Hosts and Populations
  535. [535]

    Kurbatova EV, Whitworth WC, Peddareddy LP et al.. “Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes.” Emerging infectious diseases (2025). PMID: 40023788 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications
  536. [536]

    Sewell DL. “Laboratory-associated infections and biosafety.” Clinical microbiology reviews (1995). PMID: 7553572 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  537. [537]

    Kunnath-Velayudhan S, Gennaro ML. “Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery.” Clinical microbiology reviews (2011). PMID: 21976609 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  538. [538]

    Mokrousov I. “Insights into the origin, emergence, and current spread of a successful Russian clone of Mycobacterium tuberculosis.” Clinical microbiology reviews (2013). PMID: 23554420 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  539. [539]

    Glatman-Freedman A, Casadevall A. “Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis.” Clinical microbiology reviews (1998). PMID: 9665981 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  540. [540]

    Ni R, Liu Y, Armanni A et al.. “From T-cell sensitization to molecular-intelligent stratification: a roadmap for precision diagnosis of latent tuberculosis infection.” Clinical microbiology reviews (2026). PMID: 41910258 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prognosis and Natural History, Special Hosts and Populations
  541. [541]

    Agbeyangi AO, Agrawal S, Lukose JM. “Digital health implementation research across selected African countries: a bibliometric analysis of maternal health and infectious diseases with observations on precision medicine representation (2015-2025).” Frontiers in digital health (2026). PMID: 42416812 ↗

    L5SR_OBSCited in: History and Evolution of Treatment, Prognosis and Natural History, Special Hosts and Populations
  542. [542]

    Lim J, Kim JS, Kim HW et al.. “Metabolic Disorders Are Associated With Drug-Induced Liver Injury During Antituberculosis Treatment: A Multicenter Prospective Observational Cohort Study in Korea.” Open forum infectious diseases (2023). PMID: 37654787 ↗

    L2COHORTCited in: History and Evolution of Treatment, Complications
  543. [543]

    Di Perri G, Bonora S. “Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?” The Journal of antimicrobial chemotherapy (2004). PMID: 15282233 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  544. [544]

    Prajapati YN, Gupta A, Mathew B et al.. “Role of digital media campaigns in improving TB health literacy at the community level.” The Indian journal of tuberculosis (2026). PMID: 42362246 ↗

    L1RCTCited in: History and Evolution of Treatment
  545. [545]

    Bhardwaj U, Giri N, Devkar V et al.. “Community empowerment through technology-enabled health education for tuberculosis control.” The Indian journal of tuberculosis (2026). PMID: 42362237 ↗

    L5RCTCited in: History and Evolution of Treatment
  546. [546]

    Aishwarya Rajasekhar M, Ranganathan SC, Kuppuraj MS et al.. “Impact of online community learning programs on TB prevention behaviors.” The Indian journal of tuberculosis (2026). PMID: 42362227 ↗

    L1RCTCited in: History and Evolution of Treatment
  547. [547]

    Sinha P, Jacobson KR, Horsburgh CR et al.. “At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States.” Open forum infectious diseases (2023). PMID: 37125228 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  548. [548]

    Levin BR. “The evolution and maintenance of virulence in microparasites.” Emerging infectious diseases (1996). PMID: 8903208 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  549. [549]

    Ravindran B, Hennessy D, O'Hara M et al.. “Epidemiology of Buruli Ulcer in Victoria, Australia, 2017-2022.” Emerging infectious diseases (2025). PMID: 40023793 ↗

    L2REVIEW_NARRATIVECited in: History and Evolution of Treatment
  550. [550]

    Lozano R, Naghavi M, Foreman K et al.. “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.” Lancet (London, England) (2012). PMID: 23245604 ↗

    L2OTHERCited in: History and Evolution of Treatment
  551. [551]

    Vos T, Flaxman AD, Naghavi M et al.. “Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.” Lancet (London, England) (2012). PMID: 23245607 ↗

    L2OTHERCited in: History and Evolution of Treatment
  552. [552]

    Kasamatsu A, Fukushima K, Igarashi Y et al.. “Vertebral Osteomyelitis Caused by Mycobacterium arupense Mimicking Tuberculous Spondylitis: First Reported Case and Literature Review.” Open forum infectious diseases (2023). PMID: 36726542 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  553. [553]

    Kennedy DH, Fallon RJ. “Tuberculous meningitis.” JAMA (1979). PMID: 102806 ↗

    L4OTHERCited in: History and Evolution of Treatment
  554. [554]

    Dye C, Watt CJ, Bleed DM et al.. “Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally.” JAMA (2005). PMID: 15941807 ↗

    L2OTHERCited in: History and Evolution of Treatment
  555. [555]

    Tasneen R, Garcia A, Converse PJ et al.. “Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.” Antimicrobial agents and chemotherapy (2022). PMID: 35315690 ↗

    L5OTHERCited in: History and Evolution of Treatment
  556. [556]

    Ueaphongsukkit T, Udomkarnjananun S, Vanichanan J et al.. “Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients.” The Journal of antimicrobial chemotherapy (2026). PMID: 41400843 ↗

    L4OTHERCited in: History and Evolution of Treatment, Special Hosts and Populations
  557. [557]

    Brooks MB, Hussain H, Siddiqui S et al.. “Two Clinical Prediction Tools to Inform Rapid Tuberculosis Treatment Decision-making in Children.” Open forum infectious diseases (2023). PMID: 37351457 ↗

    L2OTHERCited in: History and Evolution of Treatment
  558. [558]

    Smith JP, Song R, McCarthy KD et al.. “Clinical and Radiologic Factors Associated With Detection of Mycobacterium tuberculosis in Children Under 5 Years old Using Invasive and Noninvasive Sample Collection Techniques-Kenya.” Open forum infectious diseases (2022). PMID: 36386048 ↗

    L2OTHERCited in: History and Evolution of Treatment
  559. [559]

    Kadota JL, Musinguzi A, Aschmann HE et al.. “Adverse Events Reported During Weekly Isoniazid-Rifapentine (3HP) Tuberculosis Preventive Treatment Among People With Human Immunodeficiency Virus in Uganda.” Open forum infectious diseases (2024). PMID: 39582503 ↗

    L2OTHERCited in: History and Evolution of Treatment
  560. [560]

    Giridharan P, Nagarajan K, Selvaraju S et al.. “Estimating and Explaining the Differences in Health Care Seeking by Symptom Burden Among Persons With Presumptive Tuberculosis: Findings From a Population-Based Tuberculosis Prevalence Survey in a High-Burden Setting in India.” Open forum infectious diseases (2024). PMID: 39130083 ↗

    L2OTHERCited in: History and Evolution of Treatment
  561. [561]

    Roy Á, Gómez-Barroso D, Cruz-Ferro E et al.. “Spatiotemporal Distribution and Clinical Characteristics of Zoonotic Tuberculosis, Spain, 2018-2022.” Emerging infectious diseases (2025). PMID: 40562720 ↗

    L4OTHERCited in: History and Evolution of Treatment, Special Hosts and Populations
  562. [562]

    Mbeha B, Mine M, Motswaledi MS et al.. “Nontuberculous Mycobacteria, Botswana, 2011-2014.” Emerging infectious diseases (2019). PMID: 31211680 ↗

    L4OTHERCited in: History and Evolution of Treatment
  563. [563]

    Nellums LB, Thompson H, Holmes A et al.. “Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2018). PMID: 29779917 ↗

    L1SR_OBSCited in: Antimicrobial Resistance and Stewardship
  564. [564]

    Diacon AH, Pym A, Grobusch MP et al.. “Multidrug-resistant tuberculosis and culture conversion with bedaquiline.” The New England journal of medicine (2014). PMID: 25140958 ↗

    L1RCTCited in: Antimicrobial Resistance and Stewardship
  565. [565]

    Churchyard GJ, Swindells S, Gupta A et al.. “Preventing Multidrug-Resistant Tuberculosis: The Dawn of a New Era.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40795178 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  566. [566]

    Lienhardt C, Cook SV, Burgos M et al.. “Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.” JAMA (2011). PMID: 21486974 ↗

    L1RCTCited in: Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  567. [567]

    Jassal M, Bishai WR. “Extensively drug-resistant tuberculosis.” The Lancet. Infectious diseases (2008). PMID: 18990610 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  568. [568]

    Seddon JA, Achar J, Malik AA et al.. “Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis.” The Lancet. Infectious diseases (2025). PMID: 41036784 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  569. [569]

    Urbanowski ME, Ordonez AA, Ruiz-Bedoya CA et al.. “Cavitary tuberculosis: the gateway of disease transmission.” The Lancet. Infectious diseases (2020). PMID: 32482293 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  570. [570]

    Hwang H, Kang H, Kwon YS et al.. “Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33837767 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  571. [571]

    Pule CM, Sampson SL, Warren RM et al.. “Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy.” The Journal of antimicrobial chemotherapy (2015). PMID: 26472768 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  572. [572]

    Vernet G, Mary C, Altmann DM et al.. “Surveillance for antimicrobial drug resistance in under-resourced countries.” Emerging infectious diseases (2014). PMID: 24564906 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  573. [573]

    Tao NN, He XC, Zhang XX et al.. “Drug-Resistant Tuberculosis among Children, China, 2006-2015.” Emerging infectious diseases (2017). PMID: 29047424 ↗

    L4CASE_REPORTCited in: Antimicrobial Resistance and Stewardship
  574. [574]

    Drusano GL, Neely MN, Kim S et al.. “Building Optimal Three-Drug Combination Chemotherapy Regimens.” Antimicrobial agents and chemotherapy (2020). PMID: 32900682 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  575. [575]

    Li P, Liao Y, Zhu L et al.. “Breaking the barrier: from biosynthetic inhibition to multidimensional modulation of the mycobacterial cell wall in tuberculosis therapy.” Frontiers in pharmacology (2026). PMID: 42375609 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  576. [576]

    Liang R, Brust JCM, Reed C et al.. “Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022-2024.” Open forum infectious diseases (2026). PMID: 41541397 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship, Complications
  577. [577]

    Eddy JJ, Gadani KM, Tibbs A et al.. “Increasing Drug Resistance Among Persons With Tuberculosis in Massachusetts, 2009-2018.” Open forum infectious diseases (2020). PMID: 32855987 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  578. [578]

    Brehm TT, Schaub D, Dreyer V et al.. “Individualized Therapy Guided by Drug Susceptibility Testing for Multidrug-Resistant Tuberculosis.” Open forum infectious diseases (2026). PMID: 42369970 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  579. [579]

    Burman W, Luczynski P, Horsburgh CR et al.. “Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: a systematic review.” The Lancet. Infectious diseases (2024). PMID: 39612926 ↗

    L1TRIAL_NONRANDOMCited in: Complications
  580. [580]

    Menzies NA, Wolf E, Connors D et al.. “Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions.” The Lancet. Infectious diseases (2018). PMID: 29653698 ↗

    L2SR_OBSCited in: Complications
  581. [581]

    Mathad JS, Gupta A. “Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2012). PMID: 22942202 ↗

    L5REVIEW_NARRATIVECited in: Complications, Special Hosts and Populations
  582. [582]

    Araújo-Pereira M, Bhavaraju R, Hatherill M et al.. “From Exposure to Disease: Predicting Tuberculosis Progression.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41974032 ↗

    L5REVIEW_NARRATIVECited in: Complications
  583. [583]

    Smith PB, Cotten CM, Hudak ML et al.. “Rifampin Pharmacokinetics and Safety in Preterm and Term Infants.” Antimicrobial agents and chemotherapy (2019). PMID: 30910891 ↗

    L2TRIAL_NONRANDOMCited in: Complications
  584. [584]

    Walsh KF, McAulay K, Lee MH et al.. “Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis.” Antimicrobial agents and chemotherapy (2020). PMID: 32071052 ↗

    L2TRIAL_NONRANDOMCited in: Complications
  585. [585]

    Perumal Kannabiran B, Palaniappan NA, Manoharan T et al.. “Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial.” Open forum infectious diseases (2024). PMID: 38444824 ↗

    L1RCTCited in: Complications
  586. [586]

    Huang L, Yao Q, Gu X et al.. “1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study.” Lancet (London, England) (2021). PMID: 34454673 ↗

    L2COHORTCited in: Complications
  587. [587]

    Huang C, Huang L, Wang Y et al.. “6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.” Lancet (London, England) (2023). PMID: 37321233 ↗

    L2COHORTCited in: Complications
  588. [588]

    Chancharoenthana W, Siripoon T, Kamolratanakul S et al.. “Management of latent tuberculosis infection in patients with kidney disease.” Clinical microbiology reviews (2026). PMID: 42007724 ↗

    L5REVIEW_NARRATIVECited in: Complications, Special Hosts and Populations
  589. [589]

    Lin SY, Feng JY, Lee CY et al.. “Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study.” Antimicrobial agents and chemotherapy (2021). PMID: 33361292 ↗

    L2COHORTCited in: Complications
  590. [590]

    Atun R, Weil DE, Eang MT et al.. “Health-system strengthening and tuberculosis control.” Lancet (London, England) (2010). PMID: 20488514 ↗

    L5REVIEW_NARRATIVECited in: Complications
  591. [591]

    Rebellón-Sánchez DE, Vinueza D, Castro Restrepo DE et al.. “Cerebral tuberculoma in pregnancy (Jan 1975-May 2025): a systematic review and descriptive analysis of 33 published cases.” BMC infectious diseases (2026). PMID: 42316360 ↗

    L4SR_OBSCited in: Complications
  592. [592]

    Gou B, Wang J, Liu H et al.. “Impact of diabetes mellitus on drug-resistant tuberculosis across resistance categories: a systematic review and meta-analysis.” Journal of global health (2026). PMID: 42283258 ↗

    L2SR_OBSCited in: Complications
  593. [593]

    Mphahlele T, Makhado TG, Makhado L. “The Impact of HIV Viral Suppression and Immune Status on Rifampicin-Resistant Tuberculosis Outcomes: A Systematic Review and Meta-Analysis Protocol.” Tropical medicine and infectious disease (2026). PMID: 42347545 ↗

    L5SR_OBSCited in: Complications, Prognosis and Natural History, Special Hosts and Populations
  594. [594]

    Villalpando-Solórzano A, Ramirez-Díaz AM, Navarro-Rangel JG et al.. “Clinical Relevance of the 516 G>T Polymorphism in CYP2B6 and Its Effects on Efavirenz Concentrations in Patients with HIV and Tuberculosis: A Meta-analysis.” European journal of drug metabolism and pharmacokinetics (2026). PMID: 42337190 ↗

    L2SR_OBSCited in: Complications, Special Hosts and Populations
  595. [595]

    Yu Y, Lei F, Wang H. “Non-pharmacological therapies for patients with lymphangioleiomyomatosis: a systematic review and meta-analysis.” Frontiers in rehabilitation sciences (2026). PMID: 42312192 ↗

    L2SR_OBSCited in: Complications
  596. [596]

    Chauhan A, Sinha A, Patel Y et al.. “Viral hepatitis co-infections with tuberculosis in India: A systematic review and meta-analysis.” The Indian journal of medical research (2026). PMID: 42295712 ↗

    L2SR_OBSCited in: Complications
  597. [597]

    Mitruka K, Oeltmann JE, Ijaz K et al.. “Tuberculosis outbreak investigations in the United States, 2002-2008.” Emerging infectious diseases (2011). PMID: 21392433 ↗

    L4REVIEW_NARRATIVECited in: Complications
  598. [598]

    Zhu Q, Zhou GN, Guo J. “Economic burden of MDR/RR-TB and implementation of a treatment subsidy policy in Lishui City, China: a retrospective study following strobe guidelines.” BMC health services research (2026). PMID: 42337541 ↗

    L2COHORTCited in: Complications
  599. [599]

    Thee S, Seifart HI, Rosenkranz B et al.. “Pharmacokinetics of ethionamide in children.” Antimicrobial agents and chemotherapy (2011). PMID: 21788468 ↗

    L2OTHERCited in: Complications, Special Hosts and Populations
  600. [600]

    Maranchick NF, Martyn-Dickens C, Enimil A et al.. “Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV.” Antimicrobial agents and chemotherapy (2026). PMID: 41770228 ↗

    L2OTHERCited in: Complications, Special Hosts and Populations
  601. [601]

    Nedelman JR, Salinger DH, Subramoney V et al.. “An Exposure-Response Perspective on the Clinical Dose of Pretomanid.” Antimicrobial agents and chemotherapy (2020). PMID: 33077660 ↗

    L4OTHERCited in: Complications
  602. [602]

    Bhatt NB, Baudin E, Meggi B et al.. “Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.” The Journal of antimicrobial chemotherapy (2014). PMID: 25239466 ↗

    L1OTHERCited in: Complications
  603. [603]

    Wu IL, Chen J, Shiau R et al.. “Tuberculosis Disease Among Adults Aged 65 Years and Older: Alameda County, California, 2016-2019.” Open forum infectious diseases (2022). PMID: 36438617 ↗

    L3OTHERCited in: Complications
  604. [604]

    Apolisi I, Cox H, Tyeku N et al.. “Tuberculosis Diagnosis and Preventive Monotherapy Among Children and Adolescents Exposed to Rifampicin-Resistant Tuberculosis in the Household.” Open forum infectious diseases (2023). PMID: 36910692 ↗

    L4OTHERCited in: Complications
  605. [605]

    Katrak SS, Wang RC, Keh CE et al.. “Outcomes and Treatment-limiting Adverse Events of Patients Receiving BPaL and BPaL-FQ in California.” Open forum infectious diseases (2026). PMID: 42169695 ↗

    L4OTHERCited in: Complications
  606. [606]

    Ashkin A, Alexis A, Ninneman M et al.. “Concomitant Treatment of Tuberculosis and Hepatitis C Virus in Coinfected Patients Using Serum Drug Concentration Monitoring.” Open forum infectious diseases (2023). PMID: 37383253 ↗

    L4OTHERCited in: Complications
  607. [607]

    Talat N, Perry S, Parsonnet J et al.. “Vitamin d deficiency and tuberculosis progression.” Emerging infectious diseases (2010). PMID: 20409383 ↗

    L2OTHERCited in: Complications
  608. [608]

    Basso RP, Poester VR, Benelli JL et al.. “Disseminated Histoplasmosis in Persons with HIV/AIDS, Southern Brazil, 2010-2019.” Emerging infectious diseases (2022). PMID: 35202533 ↗

    L4OTHERCited in: Complications
  609. [609]

    Pu J, Wu S, He JQ. “Efficacy and Safety of Systematic Corticosteroids Treatment Among Patients With HIV and Tuberculosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39527080 ↗

    L1SR_MA_RCTCited in: Prognosis and Natural History
  610. [610]

    Weir IR, Wasserman S. “Treatment Effect Measures for Culture Conversion Endpoints in Phase IIb Tuberculosis Treatment Trials.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34254635 ↗

    L5SR_OBSCited in: Prognosis and Natural History
  611. [611]

    Espinosa-Pereiro J, Aguiar A, Nara E et al.. “Safety, Efficacy, and Pharmacokinetics of Daily Optimized Doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39792625 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  612. [612]

    Holmgaard FB, Guglielmetti L, Lillebaek T et al.. “Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36331978 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  613. [613]

    Nunn AJ, Phillips PPJ, Meredith SK et al.. “A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.” The New England journal of medicine (2019). PMID: 30865791 ↗

    L1RCTCited in: Prognosis and Natural History
  614. [614]

    Gillespie SH, Crook AM, McHugh TD et al.. “Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.” The New England journal of medicine (2014). PMID: 25196020 ↗

    L1RCTCited in: Prognosis and Natural History
  615. [615]

    Blanc FX, Badje AD, Bonnet M et al.. “Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults.” The New England journal of medicine (2020). PMID: 32558469 ↗

    L1RCTCited in: Prognosis and Natural History
  616. [616]

    Merle CS, Fielding K, Sow OB et al.. “A four-month gatifloxacin-containing regimen for treating tuberculosis.” The New England journal of medicine (2014). PMID: 25337748 ↗

    L1RCTCited in: Prognosis and Natural History
  617. [617]

    Bisson GP, Bastos M, Campbell JR et al.. “Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis.” Lancet (London, England) (2020). PMID: 32771107 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  618. [618]

    Ahmad N, Ahuja SD, Akkerman OW et al.. “Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.” Lancet (London, England) (2018). PMID: 30215381 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  619. [619]

    Pasipanodya J, Gumbo T. “An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.” Antimicrobial agents and chemotherapy (2010). PMID: 20937778 ↗

    L5TRIAL_NONRANDOMCited in: Prognosis and Natural History
  620. [620]

    Chang KC, Yew WW, Tam CM et al.. “WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.” Antimicrobial agents and chemotherapy (2013). PMID: 23774431 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  621. [621]

    Thiam S, LeFevre AM, Hane F et al.. “Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial.” JAMA (2007). PMID: 17244834 ↗

    L1RCTCited in: Prognosis and Natural History
  622. [622]

    Duan Y, Liu J, Lin S et al.. “The role of digital health interventions for adults with tuberculosis: a network meta-analysis of randomized controlled trials.” Frontiers in medicine (2026). PMID: 42344496 ↗

    L1SR_MA_RCTCited in: Prognosis and Natural History
  623. [623]

    Ma Z, Lienhardt C, McIlleron H et al.. “Global tuberculosis drug development pipeline: the need and the reality.” Lancet (London, England) (2010). PMID: 20488518 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History
  624. [624]

    . “Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.” Lancet (London, England) (2018). PMID: 30496104 ↗

    L2OTHERCited in: Prognosis and Natural History, Special Hosts and Populations
  625. [625]

    Leong DP, Teo KK, Rangarajan S et al.. “Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study.” Lancet (London, England) (2015). PMID: 25982160 ↗

    L2OTHERCited in: Prognosis and Natural History
  626. [626]

    Morgan E, Cleary P, Wingfield T. “Social and health factors associated with postmortem diagnosis of tuberculosis in England: a national, retrospective cohort study.” Thorax (2026). PMID: 42324093 ↗

    L2COHORTCited in: Prognosis and Natural History, Prevention and Infection Control
  627. [627]

    Benhard J, Monsel G, Dubée V et al.. “Standardized Infliximab Regimen to Treat Severe Central Nervous System Tuberculosis: A Case Series of 18 Patients.” Open forum infectious diseases (2025). PMID: 40822329 ↗

    L4CASE_REPORTCited in: Prognosis and Natural History
  628. [628]

    Sarathy JP, Via LE, Weiner D et al.. “Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.” Antimicrobial agents and chemotherapy (2018). PMID: 29203492 ↗

    L5OTHERCited in: Prognosis and Natural History
  629. [629]

    Park JS, Lee JY, Lee YJ et al.. “Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.” Antimicrobial agents and chemotherapy (2015). PMID: 26459901 ↗

    L2OTHERCited in: Prognosis and Natural History
  630. [630]

    Rigouts L, Coeck N, Gumusboga M et al.. “Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.” The Journal of antimicrobial chemotherapy (2015). PMID: 26604243 ↗

    L2OTHERCited in: Prognosis and Natural History
  631. [631]

    Loots du T. “New insights into the survival mechanisms of rifampicin-resistant Mycobacterium tuberculosis.” The Journal of antimicrobial chemotherapy (2015). PMID: 26679254 ↗

    L5OTHERCited in: Prognosis and Natural History
  632. [632]

    Macingwana L, Baker B, Ngwane AH et al.. “Sulfamethoxazole enhances the antimycobacterial activity of rifampicin.” The Journal of antimicrobial chemotherapy (2012). PMID: 22875849 ↗

    L5OTHERCited in: Prognosis and Natural History
  633. [633]

    Houghton JL, Green KD, Pricer RE et al.. “Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes.” The Journal of antimicrobial chemotherapy (2012). PMID: 23233486 ↗

    L5OTHERCited in: Prognosis and Natural History
  634. [634]

    Shi W, Zhang Y. “PhoY2 but not PhoY1 is the PhoU homologue involved in persisters in Mycobacterium tuberculosis.” The Journal of antimicrobial chemotherapy (2010). PMID: 20360062 ↗

    L5OTHERCited in: Prognosis and Natural History
  635. [635]

    Oh CT, Moon C, Choi TH et al.. “Mycobacterium marinum infection in Drosophila melanogaster for antimycobacterial activity assessment.” The Journal of antimicrobial chemotherapy (2012). PMID: 23118147 ↗

    L5OTHERCited in: Prognosis and Natural History
  636. [636]

    Cardona PJ. “Rethinking TYK2 P1104A: a flawed evolutionary trade-off in tuberculosis?” Frontiers in immunology (2026). PMID: 42382739 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History
  637. [637]

    Benastre L, Dupuy P, Gutierrez C et al.. “Effluxosomes and the evolution of metal resistance in Mycobacterium tuberculosis.” Infection and immunity (2026). PMID: 42360134 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History
  638. [638]

    Kurver L, Seers T, van Dorp S et al.. “Tuberculosis-Associated Hemophagocytic Lymphohistiocytosis: Diagnostic Challenges and Determinants of Outcome.” Open forum infectious diseases (2024). PMID: 38560612 ↗

    L4OTHERCited in: Prognosis and Natural History
  639. [639]

    Gupta A, Sun X, Krishnan S et al.. “Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings.” Open forum infectious diseases (2022). PMID: 35899273 ↗

    L1OTHERCited in: Prognosis and Natural History, Prevention and Infection Control
  640. [640]

    Millogo A, Loukil A, L'Ollivier C et al.. “Fecal Excretion of Mycobacterium leprae, Burkina Faso.” Emerging infectious diseases (2021). PMID: 34013859 ↗

    L4OTHERCited in: Prognosis and Natural History
  641. [641]

    Marras TK, Campitelli MA, Lu H et al.. “Pulmonary Nontuberculous Mycobacteria-Associated Deaths, Ontario, Canada, 2001-2013.” Emerging infectious diseases (2017). PMID: 28221106 ↗

    L2OTHERCited in: Prognosis and Natural History
  642. [642]

    Huang CC, Chu AL, Becerra MC et al.. “Mycobacterium tuberculosis Beijing Lineage and Risk for Tuberculosis in Child Household Contacts, Peru.” Emerging infectious diseases (2020). PMID: 32091363 ↗

    L2OTHERCited in: Prognosis and Natural History
  643. [643]

    Le Ray LF, Aubry A, Sougakoff W et al.. “atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure.” Emerging infectious diseases (2022). PMID: 35447056 ↗

    L4OTHERCited in: Prognosis and Natural History
  644. [644]

    Nataprawira HM, Gafar F, Risan NA et al.. “Treatment Outcomes of Childhood Tuberculous Meningitis in a Real-World Retrospective Cohort, Bandung, Indonesia.” Emerging infectious diseases (2022). PMID: 35202524 ↗

    L2OTHERCited in: Prognosis and Natural History, Prevention and Infection Control
  645. [645]

    Pedersen AA, Dahl VN, Løkke A et al.. “Mortality Rate and Cause of Death in Adults with Extrapulmonary Nontuberculous Mycobacteria Infection, Denmark.” Emerging infectious diseases (2024). PMID: 39173661 ↗

    L2OTHERCited in: Prognosis and Natural History
  646. [646]

    Nabity SA, Marks SM, Goswami ND et al.. “Characteristics of and Deaths among 333 Persons with Tuberculosis and COVID-19 in Cross-Sectional Sample from 25 Jurisdictions, United States.” Emerging infectious diseases (2023). PMID: 37647628 ↗

    L4OTHERCited in: Prognosis and Natural History
  647. [647]

    Fox GJ, Redwood L, Chang V et al.. “The Effectiveness of Individual and Environmental Infection Control Measures in Reducing the Transmission of Mycobacterium tuberculosis: A Systematic Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32502271 ↗

    L2SR_OBSCited in: Prevention and Infection Control
  648. [648]

    Wang MS, Li-Hunnam J, Chen YL et al.. “Conversion or Reversion of Interferon γ Release Assays for Mycobacterium tuberculosis Infection: A Systematic Review and Meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 38954503 ↗

    L2SR_OBSCited in: Prevention and Infection Control
  649. [649]

    Karat AS, Gregg M, Barton HE et al.. “Evidence for the Use of Triage, Respiratory Isolation, and Effective Treatment to Reduce the Transmission of Mycobacterium Tuberculosis in Healthcare Settings: A Systematic Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32502258 ↗

    L2SR_OBSCited in: Prevention and Infection Control
  650. [650]

    Conroy O, Wurie F, Collin SM et al.. “Barriers and enablers to implementing tuberculosis control strategies in EU and European Economic Area countries: a systematic review.” The Lancet. Infectious diseases (2021). PMID: 34450080 ↗

    L5SR_OBSCited in: Prevention and Infection Control
  651. [651]

    Seedat F, Hargreaves S, Nellums LB et al.. “How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review.” The Lancet. Infectious diseases (2018). PMID: 29778396 ↗

    L5SR_OBSCited in: Prevention and Infection Control
  652. [652]

    Dos Santos PCP, Messina NL, de Oliveira RD et al.. “Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial.” The Lancet. Infectious diseases (2024). PMID: 38423021 ↗

    L1RCTCited in: Prevention and Infection Control
  653. [653]

    Borges ÁH, Russell M, Tait D et al.. “Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial.” The Lancet. Infectious diseases (2025). PMID: 40056922 ↗

    L1RCTCited in: Prevention and Infection Control
  654. [654]

    Madhi SA, Nachman S, Violari A et al.. “Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.” The New England journal of medicine (2011). PMID: 21732834 ↗

    L1RCTCited in: Prevention and Infection Control
  655. [655]

    Nemes E, Geldenhuys H, Rozot V et al.. “Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.” The New England journal of medicine (2018). PMID: 29996082 ↗

    L1RCTCited in: Prevention and Infection Control
  656. [656]

    Severe P, Juste MA, Ambroise A et al.. “Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.” The New England journal of medicine (2010). PMID: 20647201 ↗

    L1RCTCited in: Prevention and Infection Control
  657. [657]

    Hakim J, Musiime V, Szubert AJ et al.. “Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.” The New England journal of medicine (2017). PMID: 28723333 ↗

    L1RCTCited in: Prevention and Infection Control
  658. [658]

    Abdool Karim SS, Naidoo K, Grobler A et al.. “Timing of initiation of antiretroviral drugs during tuberculosis therapy.” The New England journal of medicine (2010). PMID: 20181971 ↗

    L1RCTCited in: Prevention and Infection Control
  659. [659]

    Singh K. “Laboratory-acquired infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19480580 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  660. [660]

    Hasan T, Lynch M, King C et al.. “Vaccine-Preventable Disease Outbreaks Among Healthcare Workers: A Scoping Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38630638 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  661. [661]

    Beresford B, Sadoff JC. “Update on research and development pipeline: tuberculosis vaccines.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20397946 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  662. [662]

    Bodro M, Paterson DL. “Has the time come for routine trimethoprim-sulfamethoxazole prophylaxis in patients taking biologic therapies?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 23392396 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  663. [663]

    Shenoi SV, Escombe AR, Friedland G. “Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20397953 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  664. [664]

    Tameris MD, Hatherill M, Landry BS et al.. “Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.” Lancet (London, England) (2013). PMID: 23391465 ↗

    L1RCTCited in: Prevention and Infection Control
  665. [665]

    Tho DQ, Török ME, Yen NT et al.. “Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis.” Antimicrobial agents and chemotherapy (2012). PMID: 22470117 ↗

    L2RCTCited in: Prevention and Infection Control
  666. [666]

    Chigutsa E, Pasipanodya JG, Visser ME et al.. “Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.” Antimicrobial agents and chemotherapy (2014). PMID: 25313213 ↗

    L4RCTCited in: Prevention and Infection Control
  667. [667]

    Trunz BB, Fine P, Dye C. “Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness.” Lancet (London, England) (2006). PMID: 16616560 ↗

    L1SR_OBSCited in: Prevention and Infection Control
  668. [668]

    Elkington PT, Friedland JS. “Permutations of time and place in tuberculosis.” The Lancet. Infectious diseases (2015). PMID: 26321650 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  669. [669]

    Wallis RS, Kim P, Cole S et al.. “Tuberculosis biomarkers discovery: developments, needs, and challenges.” The Lancet. Infectious diseases (2013). PMID: 23531389 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  670. [670]

    Seddon JA, Godfrey-Faussett P, Hesseling AC et al.. “Management of children exposed to multidrug-resistant Mycobacterium tuberculosis.” The Lancet. Infectious diseases (2012). PMID: 22373591 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  671. [671]

    Parwati I, van Crevel R, van Soolingen D. “Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains.” The Lancet. Infectious diseases (2010). PMID: 20113979 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  672. [672]

    Becerra MC, Appleton SC, Franke MF et al.. “Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study.” Lancet (London, England) (2010). PMID: 21145581 ↗

    L2COHORTCited in: Prevention and Infection Control
  673. [673]

    Dannenberg AM. “Perspectives on clinical and preclinical testing of new tuberculosis vaccines.” Clinical microbiology reviews (2010). PMID: 20930073 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  674. [674]

    Ganmaa D, Khudyakov P, Buyanjargal U et al.. “Prevalence and Determinants of QuantiFERON-Diagnosed Tuberculosis Infection in 9810 Mongolian Schoolchildren.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30481273 ↗

    L4OTHERCited in: Prevention and Infection Control
  675. [675]

    Bertumen JB, Pascopella L, Han E et al.. “Epidemiology and Treatment Outcomes of Tuberculosis With Chronic Hepatitis B Infection-California, 2016-2020.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38531668 ↗

    L2OTHERCited in: Prevention and Infection Control
  676. [676]

    van Cutsem G, Isaakidis P, Farley J et al.. “Infection Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the Key.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2016). PMID: 27118853 ↗

    L5OTHERCited in: Prevention and Infection Control
  677. [677]

    Hasse B, Walker AS, Fehr J et al.. “Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.” Antimicrobial agents and chemotherapy (2014). PMID: 24514096 ↗

    L2COHORTCited in: Prevention and Infection Control
  678. [678]

    Kaufmann SH, Hussey G, Lambert PH. “New vaccines for tuberculosis.” Lancet (London, England) (2010). PMID: 20488515 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  679. [679]

    Hoft DF. “Tuberculosis vaccine development: goals, immunological design, and evaluation.” Lancet (London, England) (2008). PMID: 18620952 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  680. [680]

    Huffman MD, Xavier D, Perel P. “Uses of polypills for cardiovascular disease and evidence to date.” Lancet (London, England) (2017). PMID: 28290995 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  681. [681]

    Kamarulzaman A, Reid SE, Schwitters A et al.. “Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners.” Lancet (London, England) (2016). PMID: 27427456 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  682. [682]

    McCoy D, Kembhavi G, Patel J et al.. “The Bill & Melinda Gates Foundation's grant-making programme for global health.” Lancet (London, England) (2009). PMID: 19427959 ↗

    L2REVIEW_NARRATIVECited in: Prevention and Infection Control
  683. [683]

    Yahav D, Gitman MR, Margalit I et al.. “Screening for Latent Tuberculosis Infection in Solid Organ Transplant Recipients to Predict Active Disease: A Systematic Review and Meta-Analysis of Diagnostic Studies.” Open forum infectious diseases (2023). PMID: 37559757 ↗

    L1SR_OBSCited in: Prevention and Infection Control
  684. [684]

    Alanazi YN, Alotaibi AM, Bahakam AS et al.. “Prevalence of latent tuberculosis infection among healthcare workers in Saudi Arabia: a systematic review and meta-analysis.” BMC public health (2026). PMID: 42226180 ↗

    L1SR_OBSCited in: Prevention and Infection Control
  685. [685]

    Pai M, Dheda K, Cunningham J et al.. “T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward.” The Lancet. Infectious diseases (2007). PMID: 17521596 ↗

    L5OTHERCited in: Prevention and Infection Control
  686. [686]

    Ou X, Liu G, Peng B et al.. “Safety, tolerability, and concordance with interferon-γ release assays of a recombinant ESAT6-MPT64 skin test: a phase 1 randomized clinical trial.” Frontiers in immunology (2026). PMID: 42136669 ↗

    L1RCTCited in: Prevention and Infection Control
  687. [687]

    Ter Steeg L, Domínguez-Andrés J, Netea MG et al.. “Trained Immunity as a Preventive Measure for Surgical Site Infections.” Clinical microbiology reviews (2021). PMID: 34585978 ↗

    L5OTHERCited in: Prevention and Infection Control
  688. [688]

    Epstein DJ, Dunn J, Deresinski S. “Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management.” Open forum infectious diseases (2018). PMID: 30094293 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  689. [689]

    McNamara BJ, Blasdell KR, Yerramilli A et al.. “Comprehensive Case-Control Study of Protective and Risk Factors for Buruli Ulcer, Southeastern Australia.” Emerging infectious diseases (2023). PMID: 37735741 ↗

    L3CASE_CONTROLCited in: Prevention and Infection Control
  690. [690]

    Cai S, Xia Y, Zhou Y et al.. “Multidimensional determinants of BCG-induced false-positivity in tuberculin skin testing: a global meta-analysis of 242 studies.” European respiratory review : an official journal of the European Respiratory Society (2026). PMID: 42203236 ↗

    L1SR_OBSCited in: Prevention and Infection Control
  691. [691]

    . “Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.” Lancet (London, England) (2025). PMID: 41092926 ↗

    L2OTHERCited in: Prevention and Infection Control, Special Hosts and Populations
  692. [692]

    Akbar EA, Tukiran T, Sanjaya IGM et al.. “Vaccine development against Mycobacterium tuberculosis: a PRISMA-guided systematic review of conventional and computational multi-epitope approaches.” Clinical and experimental vaccine research (2026). PMID: 42099698 ↗

    L1SR_OBSCited in: Prevention and Infection Control
  693. [693]

    Gu R, Wang L. “Efficacy of Mycobacterium vaccae and vitamin D combination therapy in initial smear-negative pulmonary tuberculosis: a prospective study.” Frontiers in medicine (2026). PMID: 42100276 ↗

    L2COHORTCited in: Prevention and Infection Control
  694. [694]

    Denti P, Garcia-Prats AJ, Draper HR et al.. “Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.” Antimicrobial agents and chemotherapy (2018). PMID: 29133560 ↗

    L4OTHERCited in: Prevention and Infection Control
  695. [695]

    Carrigy NB, Larsen SE, Reese V et al.. “Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29.” Antimicrobial agents and chemotherapy (2019). PMID: 31527037 ↗

    L5OTHERCited in: Prevention and Infection Control
  696. [696]

    Thee S, Garcia-Prats AJ, McIlleron HM et al.. “Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.” Antimicrobial agents and chemotherapy (2014). PMID: 24550337 ↗

    L4OTHERCited in: Prevention and Infection Control
  697. [697]

    Crowther-Gibson P, Cohen C, Klugman KP et al.. “Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008.” Antimicrobial agents and chemotherapy (2012). PMID: 22802256 ↗

    L3OTHERCited in: Prevention and Infection Control
  698. [698]

    Ogwang S, Good CE, Okware B et al.. “Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis.” Antimicrobial agents and chemotherapy (2015). PMID: 26169400 ↗

    L4OTHERCited in: Prevention and Infection Control
  699. [699]

    Fortún J, Martín-Dávila P, Molina A et al.. “Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation?” The Journal of antimicrobial chemotherapy (2007). PMID: 17392354 ↗

    L4OTHERCited in: Prevention and Infection Control
  700. [700]

    Picchio CA, Nicolàs A, Duffell E et al.. “From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe.” The Lancet regional health. Europe (2026). PMID: 42266911 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  701. [701]

    Hatherill M, Clark RA, Martinez L et al.. “Inclusion of young adolescents in policy development for new tuberculosis vaccines.” The Lancet. Global health (2026). PMID: 42259345 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  702. [702]

    Druszczynska M, Sadowska B, Kulesza J et al.. “Bacillus Calmette-Guérin (BCG) Vaccination and the Immune-Brain Axis: Implications for Neuroprotection and Neurodegenerative Disease.” Vaccines (2026). PMID: 42188786 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  703. [703]

    Cardona PJ. “Reinfection as a central constraint on tuberculosis vaccine development.” Frontiers in immunology (2026). PMID: 42093996 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  704. [704]

    Kain D, Lewinsohn DM, Lewinsohn DA. “Role of Donor Unrestricted T Cells (DURTs) in TB Host Defense: Implications for Novel TB Vaccine Development.” Vaccines (2026). PMID: 42042841 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  705. [705]

    Wick JM, Ni Y, Halmer N et al.. “Tuberculosis and Chronic Hepatitis B Virus Infection Screening Among Non-US-Born Persons in an Integrated Health System in California.” Open forum infectious diseases (2024). PMID: 39296340 ↗

    L4OTHERCited in: Prevention and Infection Control
  706. [706]

    Makinson A, Park LS, Stone K et al.. “Risks of Opportunistic Infections in People With Human Immunodeficiency Virus With Cancers Treated With Chemotherapy.” Open forum infectious diseases (2021). PMID: 34458394 ↗

    L2OTHERCited in: Prevention and Infection Control
  707. [707]

    West E, Chaudron SE, Russenberger D et al.. “Safety of Bacillus Calmette-Guérin Vaccination and Impact on HIV-1 Latent Reservoir Size in People With Treated HIV-1 Infection.” Open forum infectious diseases (2025). PMID: 41127455 ↗

    L1OTHERCited in: Prevention and Infection Control
  708. [708]

    Walaza S, Tempia S, von Gottberg A et al.. “Risk Factors for Severe Coronavirus Disease 2019 Among Human Immunodeficiency Virus-Infected and -Uninfected Individuals in South Africa, April 2020-March 2022: Data From Sentinel Surveillance.” Open forum infectious diseases (2022). PMID: 36570970 ↗

    L2OTHERCited in: Prevention and Infection Control
  709. [709]

    Dyer KE, Russell R, Nafiz R et al.. “Effectiveness of an Embedded Infectious Disease Screening, Treatment, and Prevention Intervention Within an Inpatient Substance Use Treatment Program.” Open forum infectious diseases (2025). PMID: 40756650 ↗

    L4OTHERCited in: Prevention and Infection Control
  710. [710]

    Lamb GS, Cruz AT, Camp EA et al.. “Tuberculosis in Internationally Displaced Children Resettling in Harris County, Texas, USA, 2010-20151.” Emerging infectious diseases (2020). PMID: 32687465 ↗

    L4OTHERCited in: Prevention and Infection Control
  711. [711]

    Yen YF, Pan SW, Su VY et al.. “Influenza Vaccination and Incident Tuberculosis among Elderly Persons, Taiwan1.” Emerging infectious diseases (2018). PMID: 29460733 ↗

    L2OTHERCited in: Prevention and Infection Control
  712. [712]

    Zhang G, Zhang Y, Zhong D et al.. “High Prevalence of and Risk Factors for Latent Tuberculosis Infection among Prisoners, Tianjin, China.” Emerging infectious diseases (2020). PMID: 32091373 ↗

    L4OTHERCited in: Prevention and Infection Control
  713. [713]

    Murphree R, Warkentin JV, Dunn JR et al.. “Elephant-to-human transmission of tuberculosis, 2009.” Emerging infectious diseases (2011). PMID: 21392425 ↗

    L2OTHERCited in: Prevention and Infection Control
  714. [714]

    Cruz AT, Starke JR. “Window Period Prophylaxis for Children Exposed to Tuberculosis, Houston, Texas, USA, 2007-2017.” Emerging infectious diseases (2019). PMID: 30789136 ↗

    L4OTHERCited in: Prevention and Infection Control
  715. [715]

    Pooransingh S, Sakhamuri S. “Need for BCG Vaccination to Prevent TB in High-Incidence Countries and Populations.” Emerging infectious diseases (2020). PMID: 31922950 ↗

    L5OTHERCited in: Prevention and Infection Control
  716. [716]

    Malik AA, Gandhi NR, Lash TL et al.. “Effectiveness of Preventive Therapy for Persons Exposed at Home to Drug-Resistant Tuberculosis, Karachi, Pakistan.” Emerging infectious diseases (2021). PMID: 33624580 ↗

    L4OTHERCited in: Prevention and Infection Control
  717. [717]

    Badiaga S, Raoult D, Brouqui P. “Preventing and controlling emerging and reemerging transmissible diseases in the homeless.” Emerging infectious diseases (2008). PMID: 18760000 ↗

    L5OTHERCited in: Prevention and Infection Control
  718. [718]

    Khan FA, Minion J, Pai M et al.. “Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20353364 ↗

    L2SR_OBSCited in: Special Hosts and Populations
  719. [719]

    Getahun H, Gunneberg C, Granich R et al.. “HIV infection-associated tuberculosis: the epidemiology and the response.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20397949 ↗

    L5REVIEW_NARRATIVECited in: Special Hosts and Populations
  720. [720]

    Howard AA, El-Sadr WM. “Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20397954 ↗

    L5REVIEW_NARRATIVECited in: Special Hosts and Populations
  721. [721]

    Coovadia A, Abrams EJ, Strehlau R et al.. “Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.” JAMA (2015). PMID: 26529159 ↗

    L1RCTCited in: Special Hosts and Populations
  722. [722]

    Weiner M, Egelund EF, Engle M et al.. “Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.” The Journal of antimicrobial chemotherapy (2013). PMID: 24343893 ↗

    L4TRIAL_NONRANDOMCited in: Special Hosts and Populations
  723. [723]

    Kurbatova EV, Whitworth WC, Bryant KE et al.. “Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020.” Emerging infectious diseases (2025). PMID: 41490808 ↗

    L2TRIAL_NONRANDOMCited in: Special Hosts and Populations
  724. [724]

    Pastick KA, Kagimu E, Dobbin J et al.. “Pregnancy-Related Tuberculous Meningitis and Immune Reconstitution Inflammatory Syndrome: A Case Series and Systematic Review.” Open forum infectious diseases (2022). PMID: 36267255 ↗

    L4SR_OBSCited in: Special Hosts and Populations
  725. [725]

    . “Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.” The Lancet. Infectious diseases (2024). PMID: 38640940 ↗

    L2OTHERCited in: Special Hosts and Populations
  726. [726]

    Shrivastav VN, Akurathi HK, Kalariya H et al.. “Anemia burden in tuberculosis patients across Southeast Asia: a systematic review and meta-analysis.” BMC pulmonary medicine (2026). PMID: 42393625 ↗

    L1SR_OBSCited in: Special Hosts and Populations
  727. [727]

    Balinda IG, Sugrue DD, Ivers LC. “More Than Malnutrition: A Review of the Relationship Between Food Insecurity and Tuberculosis.” Open forum infectious diseases (2019). PMID: 30949541 ↗

    L5REVIEW_NARRATIVECited in: Special Hosts and Populations
  728. [728]

    Mirza M, Grant-Greene Y, Valles MPJS et al.. “Leveraging PEPFAR-Supported Health Information Systems for COVID-19 Pandemic Response.” Emerging infectious diseases (2022). PMID: 36502426 ↗

    L5REVIEW_NARRATIVECited in: Special Hosts and Populations
  729. [729]

    . “Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.” Lancet (London, England) (2018). PMID: 30496103 ↗

    L2OTHERCited in: Special Hosts and Populations
  730. [730]

    Ouedraogo D, Cissoko Y, Soumare M et al.. “Neuromeningeal Cryptococcosis and Tuberculosis Coinfection in Bamako: A One-Year Case Series.” Open forum infectious diseases (2023). PMID: 37663093 ↗

    L4CASE_REPORTCited in: Special Hosts and Populations
  731. [731]

    Dieleman JL, Graves C, Johnson E et al.. “Sources and Focus of Health Development Assistance, 1990-2014.” JAMA (2015). PMID: 26080340 ↗

    L2OTHERCited in: Special Hosts and Populations
  732. [732]

    Lowenthal ED, Ellenberg JH, Machine E et al.. “Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.” JAMA (2013). PMID: 23632724 ↗

    L3OTHERCited in: Special Hosts and Populations
  733. [733]

    Van Schalkwyk M, Bekker A, Decloedt E et al.. “Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study.” Antimicrobial agents and chemotherapy (2025). PMID: 40741959 ↗

    L2OTHERCited in: Special Hosts and Populations
  734. [734]

    Roberts O, Khoo S, Owen A et al.. “Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro.” Antimicrobial agents and chemotherapy (2017). PMID: 28193650 ↗

    L5OTHERCited in: Special Hosts and Populations
  735. [735]

    Kawuma AN, Wasmann RE, Dooley KE et al.. “Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin.” Antimicrobial agents and chemotherapy (2022). PMID: 35604212 ↗

    L2OTHERCited in: Special Hosts and Populations
  736. [736]

    Sundell J, Bienvenu E, Birgersson S et al.. “Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.” Antimicrobial agents and chemotherapy (2022). PMID: 36069614 ↗

    L4OTHERCited in: Special Hosts and Populations
  737. [737]

    Phaisal W, Albitar O, Chariyavilaskul P et al.. “Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.” The Journal of antimicrobial chemotherapy (2024). PMID: 38661209 ↗

    L4OTHERCited in: Special Hosts and Populations
  738. [738]

    Crouch SH, Kolkenbeck-Ruh A, Kahn K et al.. “Cash transfers targeting adolescent wellbeing: a scoping review of the literature in low- and middle-income countries.” Global health action (2026). PMID: 42339848 ↗

    L5REVIEW_NARRATIVECited in: Special Hosts and Populations
  739. [739]

    Wailagala A, Okello S, Kayondo W et al.. “Long-Term Mortality among Hospitalized Adults with Sepsis in Uganda: A Prospective Cohort Study.” The American journal of tropical medicine and hygiene (2026). PMID: 42392067 ↗

    L2COHORTCited in: Special Hosts and Populations
  740. [740]

    Houck K, Chakhaia T, Gorvetzian S et al.. “Diabetes Mellitus and Tuberculosis Treatment Outcomes: Interaction Assessment Between Hyperglycemia and Human Immunodeficiency Virus in the State of Georgia, 2015-2020.” Open forum infectious diseases (2023). PMID: 37383249 ↗

    L3OTHERCited in: Special Hosts and Populations
  741. [741]

    Nagot N, Hai VV, Dong TTT et al.. “Alarming Tuberculosis Rate Among People Who Inject Drugs in Vietnam.” Open forum infectious diseases (2021). PMID: 35106311 ↗

    L4OTHERCited in: Special Hosts and Populations
  742. [742]

    Mandalakas AM, Kay AW, Bacha JM et al.. “Tuberculosis among Children and Adolescents at HIV Treatment Centers in Sub-Saharan Africa.” Emerging infectious diseases (2020). PMID: 33219815 ↗

    L3OTHERCited in: Special Hosts and Populations
  743. [743]

    Lukoye D, Gustavson G, Namuwenge PM et al.. “Tuberculosis Preventive Therapy among Persons Living with HIV, Uganda, 2016-2022.” Emerging infectious diseases (2023). PMID: 36823496 ↗

    L4OTHERCited in: Special Hosts and Populations

Revision History

All updates applied to this page

Loading revisions…